Skip to the page
Get started – free

Data / Research funding / Prostate Cancer

Prostate Cancer: 978 NIH awards ($1.2B) to 240 organizations

978 NIH awards ($1.2B) in the NIH spending category Prostate Cancer, to 240 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards on Prostate CancerWatch Prostate Cancer
Topic
NIH spending category

Awards

The 500 largest of 978 awards in the window.

AwardAgencyInstitute or divisionFiscal yearAmount in windowStartEndPrincipal investigatorSource
NCI Early Career Cancer Clinical Investigator AwardNIHNational Cancer Institute2021 to 2025$65,560,307March 10, 1997November 30, 2026EBERT, BENJAMIN LEVINEreporter.nih.gov
Mayo Clinic Comprehensive Cancer Center Support GrantNIHNational Cancer Institute2021 to 2025$29,249,641April 25, 1997August 31, 2030WILLMAN, CHERYL LYNNreporter.nih.gov
TO PROVIDE SEQUENCING SERVICES USING WHOLE GENOME SEQUENCING (GERMLINE FFPE) FOR NCI (KLEIN)NIHNational Heart, Lung, and Blood Institute2021 to 2023$24,069,896September 27, 2023December 31, 2025DOHENY, KIMreporter.nih.gov
Center for Pre-Clinical Cancer ResearchNIHNational Institute of General Medical Sciences2021 to 2025$11,277,290March 1, 2021February 28, 2027FRANCIS, JOSEPHreporter.nih.gov
The Pacific Northwest Prostate Cancer SPORENIHNational Cancer Institute2021 to 2025$9,924,776September 19, 2002August 31, 2028NELSON, PETER Sreporter.nih.gov
iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials ConsortiumNIHNational Cancer Institute2021 to 2025$7,046,172August 15, 2019July 31, 2031VILAR SANCHEZ, EDUARDOreporter.nih.gov
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareNIHNational Cancer Institute2021 to 2025$5,422,908March 5, 2019February 28, 2026BURSTEIN, HAROLD JOHNreporter.nih.gov
Genomic and Genomic Variation in Prostate CancerNIHNational Cancer Institute2022 to 2025$5,164,514January 7, 2022April 30, 2027REBBECK, TIMOTHY RICHARDreporter.nih.gov
Human Prostate Tumor Atlas CenterNIHNational Cancer Institute2024 to 2025$5,162,603September 1, 2024August 31, 2029DING, LIreporter.nih.gov
Integrating targeted therapy and immunotherapy to break through cancerNIHNational Cancer Institute2021 to 2025$5,025,838September 1, 2016August 31, 2030ZHAO, JEANreporter.nih.gov
Modeling Precision Interventions for Prostate Cancer ControlNIHNational Cancer Institute2021 to 2025$4,423,369June 15, 2025August 31, 2026ETZIONI, RUTH Dreporter.nih.gov
Modeling and analytics for cancer diagnostics: traversing the data-evidence divideNIHNational Cancer Institute2022 to 2025$3,872,365September 1, 2022August 31, 2029ETZIONI, RUTH Dreporter.nih.gov
GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic healthNIHEunice Kennedy Shriver National Institute of Child Health & Human Development2021 to 2025$3,803,952September 1, 2021May 31, 2027HOTALING, JAMESreporter.nih.gov
Genetic Predictors of Prostate Cancer SurvivalNIHNational Cancer Institute2021 to 2025$3,655,797January 15, 2021December 31, 2026KLEIN, ROBERT J.reporter.nih.gov
Exploring Precision Oncology: From Gene Fusions to lncRNAsNIHNational Cancer Institute2021 to 2024$3,631,025September 1, 2018August 31, 2025CHINNAIYAN, ARUL Mreporter.nih.gov
PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapyNIHNational Cancer Institute2021 to 2025$3,606,632July 1, 2021June 30, 2027GRIMM, JANreporter.nih.gov
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancerNIHNational Cancer Institute2021 to 2025$3,403,254February 9, 2021January 31, 2027GOLDKORN, AMIRreporter.nih.gov
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesNIHNational Cancer Institute2021 to 2025$3,352,278March 2, 2021February 28, 2027FREEDMAN, MATTHEW Lreporter.nih.gov
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesNIHNational Cancer Institute2022 to 2025$3,342,109September 1, 2022August 31, 2027FREEDMAN, MATTHEW Lreporter.nih.gov
Career Development in Pediatric and Medical OncologyNIHNational Cancer Institute2021 to 2025$3,314,336September 30, 1997August 31, 2026MESHINCHI, SOHEILreporter.nih.gov
Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy MonitoringNIHNational Cancer Institute2021 to 2025$3,288,067December 1, 2020November 30, 2026VIGNERON, DANIEL Breporter.nih.gov
Hyperpolarized C-13 MRI Techniques to Monitor Radiation Therapy Response in Prostate Cancer PatientsNIHNational Cancer Institute2021 to 2025$3,266,535July 1, 2021June 30, 2027VIGNERON, DANIEL Breporter.nih.gov
Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer ResearchNIHNational Cancer Institute2021 to 2023$3,239,571September 20, 2019August 31, 2025LIN, DANIEL W.reporter.nih.gov
Pathomic Predictors of Prostate Cancer ProgressionNIHNational Cancer Institute2021 to 2024$3,202,938April 16, 2020March 31, 2026MALLICK, PARAG KUMARreporter.nih.gov
3D High Resolution Magnetic Resonance Fingerprinting for Prostate CancerNIHNational Cancer Institute2021 to 2025$3,177,909August 1, 2021July 31, 2027JIANG, YUNreporter.nih.gov
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancerNIHNational Cancer Institute2021 to 2025$3,177,343July 8, 2021June 30, 2027YANG, HUSHANreporter.nih.gov
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternNIHNational Cancer Institute2021 to 2025$3,170,165March 29, 2005June 30, 2028SANDA, MARTIN G.reporter.nih.gov
Enabling clinical tissue microstructure imaging as a diagnostic tool in wide-bore 3T MRINIHNational Institute of Biomedical Imaging and Bioengineering2023 to 2025$3,146,296September 1, 2023August 31, 2028FOO, THOMAS Kreporter.nih.gov
Transrectal Histotripsy for Focal Ablation of Prostate CancerNIHNational Cancer Institute2022 to 2025$3,132,373September 23, 2022August 31, 2027SCHADE, GEORGE Rreporter.nih.gov
A transdisciplinary approach for dissecting stem cell states in prostate cancerNIHNational Cancer Institute2021 to 2025$3,070,312September 20, 2021August 31, 2026RABADAN, RAULreporter.nih.gov
Multiethnic GWAS and TWAS to Inform Risk Prediction for Prostate CancerNIHNational Cancer Institute2021 to 2025$3,068,628May 1, 2025April 30, 2027HAIMAN, CHRISTOPHER ALANreporter.nih.gov
Patient-Derived Models of Prostate Cancer for Personalized MedicineNIHNational Cancer Institute2021 to 2023$3,037,013August 1, 2019July 31, 2025FUTREAL, PHILLIP ANDREWreporter.nih.gov
Identifying factors associated with prostate cancer progression and survival in African American men: The RESPOND CohortNIHNational Cancer Institute2024 to 2025$3,024,739July 23, 2024June 30, 2029HAIMAN, CHRISTOPHER ALANreporter.nih.gov
Prognostic and Predictive Digital Tissue Image Assay for Prostate CancerNIHNational Cancer Institute2022 to 2025$3,008,190September 5, 2022August 31, 2027MADABHUSHI, ANANTreporter.nih.gov
Computer Aided Diagnostic System for Prostate Cancer Detection Using Quantitative Multiparametric MRINIHNational Cancer Institute2021 to 2025$2,990,455September 23, 2021August 31, 2027METZGER, GREGORY JOHNreporter.nih.gov
Prostate Cancer Radio-Pathomics for Differentiating Clinically Significant DiseaseNIHNational Cancer Institute2021 to 2025$2,965,890March 1, 2021August 31, 2026LAVIOLETTE, PETER Sreporter.nih.gov
Molecular mechanisms underlying lineage plasticity in prostate cancerNIHNational Cancer Institute2021 to 2025$2,937,823April 1, 2025March 31, 2027BELTRAN, HIMISHAreporter.nih.gov
Early clinial trials for Angelica herbal supplements for prostate cancer interceptionNIHNational Cancer Institute2022 to 2025$2,932,860September 1, 2022August 31, 2027LU, JUNXUANreporter.nih.gov
Preventing invasive prostate cancerNIHNational Cancer Institute2023 to 2025$2,928,553September 19, 2023August 31, 2028BERGAN, RAYMOND C.reporter.nih.gov
OpenIGTLink: a network communication interface for closed-loop image-guided interventionsNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2024$2,909,122July 1, 2015January 31, 2026TOKUDA, JUNICHIreporter.nih.gov
Understanding and targeting epigentic regulation of immune evasion in prostate cancerNIHNational Cancer Institute2025$2,895,540August 1, 2025July 31, 2029CAI, LINGreporter.nih.gov
Targeting apoptotic cells to enhance radiotherapyNIHNational Cancer Institute2022 to 2025$2,817,814September 22, 2022August 31, 2027RAO, JIANGHONGreporter.nih.gov
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate CancerNIHNational Cancer Institute2021 to 2024$2,771,966July 1, 2020June 30, 2025FENG, FELIX YI-CHUNGreporter.nih.gov
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and EuropeansNIHNational Cancer Institute2022 to 2025$2,762,045July 1, 2022June 30, 2027WU, LANGreporter.nih.gov
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRINIHNational Cancer Institute2021 to 2024$2,760,490September 7, 2020August 31, 2025KURHANEWICZ, JOHNreporter.nih.gov
High throughput infrastructure for reaction screening and bioassaysNIHNational Center for Advancing Translational Sciences2024 to 2025$2,752,647June 29, 2022May 31, 2027COOKS, ROBERT GRAHAMreporter.nih.gov
Investigating the mechanisms of driver genes associated with ancestry and aggressiveness in prostate cancerNIHNational Cancer Institute2021 to 2025$2,739,005May 10, 2021April 30, 2027CAMPBELL, JOSHUA Dreporter.nih.gov
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapyNIHNational Cancer Institute2022 to 2025$2,733,165May 1, 2022April 30, 2027PILLARSETTY, NAGAVARAKISHOREreporter.nih.gov
Systemic RNA Delivery to TumorsNIHNational Cancer Institute2021 to 2025$2,731,905December 21, 2015June 30, 2027SHI, JINJUNreporter.nih.gov
DNA repair gene mutations and prostate cancerNIHNational Cancer Institute2021 to 2024$2,728,204December 2, 2019November 30, 2025SHEN, BINGHUIreporter.nih.gov
Metastasis of PTEN Mutant Prostate CancerNIHNational Cancer Institute2022 to 2025$2,701,454September 1, 2022August 31, 2027TROTMAN, LLOYD Creporter.nih.gov
Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunctionNIHNational Cancer Institute2021 to 2025$2,692,281July 6, 2021June 30, 2026MORAN, AMY Ereporter.nih.gov
Plk1 as a prognostic biomarker for prostate cancerNIHNational Cancer Institute2021 to 2025$2,686,273July 1, 2021June 30, 2026LIU, XIAOQIreporter.nih.gov
Development of large-field-of-view hyperpolarized MRINIHNational Cancer Institute2021 to 2024$2,676,537December 1, 2019November 30, 2024KESHARI, KAYVAN Rreporter.nih.gov
Physician Assistance Technology in Image-guided Robotic Intervention of ProstateNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2024$2,661,260August 1, 2021April 30, 2026HATA, NOBUHIKOreporter.nih.gov
Clinical Qualification of Imaging and Fluid-Based Tumor Monitoring Biomarkers for Metastatic Castration Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$2,654,692July 1, 2020June 30, 2026SCHWARTZ, LAWRENCE Hreporter.nih.gov
Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory TherapyNIHNational Cancer Institute2022 to 2025$2,642,372September 1, 2022August 31, 2027YAMOAH, KOSJreporter.nih.gov
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate CancerNIHNational Cancer Institute2022 to 2025$2,630,502September 20, 2022August 31, 2027PATNAIK, AKASHreporter.nih.gov
Nerve-Specific Fluorophores for Improved Nerve Sparing during Prostatectomy using the Clinical Fluorescence Guided Surgery InfrastructureNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2024$2,627,891August 5, 2021April 30, 2026GIBBS, SUMMER LYNNEreporter.nih.gov
PSMA-targeted AuNPs for MR guided radiotherapy and radiosensitizationNIHNational Cancer Institute2021 to 2024$2,622,473March 1, 2021February 28, 2026BASILION, JAMES PETERreporter.nih.gov
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate CancerNIHNational Cancer Institute2021 to 2024$2,618,639February 1, 2020January 31, 2026OJIMA, IWAOreporter.nih.gov
Enhancing the Efficacy of Docetaxel in Prostate CancerNIHNational Cancer Institute2022 to 2025$2,590,555July 13, 2022June 30, 2027BALK, STEVEN P.reporter.nih.gov
Identifying Cancer Recurrence with Novel Data Linkages with a Cancer RegistryNIHNational Cancer Institute2022 to 2025$2,585,593August 1, 2022July 31, 2027DOHERTY, JENNIFER ANNEreporter.nih.gov
Molecular Determinants of Social Factors in Prostate CancerNIHNational Institute on Minority Health and Health Disparities2021$2,560,268September 26, 2017July 31, 2023KUMAR, DEEPAKreporter.nih.gov
Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate CancerNIHNational Cancer Institute2022 to 2025$2,551,647January 1, 2022December 31, 2026MAHER, CHRISTOPHER Areporter.nih.gov
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCNIHNational Cancer Institute2022 to 2025$2,528,918September 16, 2020December 31, 2026HALABI, SUSANreporter.nih.gov
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer PatientsNIHNational Cancer Institute2022 to 2025$2,508,029December 17, 2021November 30, 2026PEPPONE, LUKE JOSEPHreporter.nih.gov
Highly selective targeted theranostics for prostate cancersNIHNational Cancer Institute2021 to 2024$2,486,011August 11, 2021July 31, 2026BASILION, JAMES PETERreporter.nih.gov
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase MicrofluidicsNIHNational Cancer Institute2021 to 2024$2,478,422February 3, 2020January 31, 2026BEEBE, DAVID Jreporter.nih.gov
Preclinical analyses of advanced prostate cancer in genetically-engineered miceNIHNational Cancer Institute2021 to 2025$2,462,511August 6, 2013January 31, 2028ABATE-SHEN, CORYreporter.nih.gov
Multifunctional Regulation of Prostate Cancer Metabolism by Sigma1 ModulatorsNIHNational Cancer Institute2021 to 2024$2,461,554January 13, 2020December 31, 2025KIM, FELIX JINHYUNreporter.nih.gov
Multichannel Fluorescence Guided Surgery Tools Enabling Simultaneous Cancer Margin and Nerve Visualization in ProstatectomyNIHNational Cancer Institute2022 to 2025$2,453,547May 10, 2022April 30, 2027GIBBS, SUMMER LYNNEreporter.nih.gov
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgensNIHNational Cancer Institute2022 to 2025$2,436,399September 1, 2022July 31, 2027MCDONNELL, DONALD Preporter.nih.gov
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer ClassificationNIHNational Cancer Institute2021 to 2024$2,427,569March 1, 2020February 28, 2026SUNG, KYUNG HYUNreporter.nih.gov
Enhancing the efficacy of androgen signaling inhibitors in prostate cancerNIHNational Cancer Institute2021 to 2025$2,422,948July 1, 2021June 30, 2026LIU, XIAOQIreporter.nih.gov
Precision Prostate Cancer Screening with Genetically Adjusted Prostate-Specific Antigen LevelsNIHNational Cancer Institute2021 to 2025$2,414,500April 1, 2020March 31, 2030WITTE, JOHN S.reporter.nih.gov
Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL)NIHNational Cancer Institute2022 to 2025$2,411,833February 4, 2022July 31, 2028HU, JIMreporter.nih.gov
PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?NIHNational Cancer Institute2022 to 2025$2,408,587March 1, 2022February 28, 2027BAHLER, CLINTON DAVIDreporter.nih.gov
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancerNIHNational Cancer Institute2022 to 2025$2,406,187April 1, 2022March 31, 2027TONER, MEHMETreporter.nih.gov
Targeting Castration Resistant Prostate Cancer via Potent Inhibition of Signaling LipidsNIHNational Cancer Institute2022 to 2025$2,404,562September 1, 2022August 31, 2027KAOCHAR, SALMAreporter.nih.gov
Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate CancerNIHNational Cancer Institute2024 to 2025$2,399,998September 2, 2024August 31, 2026LANGTON-WEBSTER, BEATRICEreporter.nih.gov
Development of Enabling Technologies for Clinical Ultrahigh Field Body MRINIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2024$2,392,254April 15, 2021December 31, 2025METZGER, GREGORY JOHNreporter.nih.gov
Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer DetectionNIHNational Cancer Institute2021 to 2024$2,384,687September 11, 2020June 30, 2025HU, JIMreporter.nih.gov
Ultra-Low Count Quantitative SPECT for Alpha-Particle TherapiesNIHNational Institute of Biomedical Imaging and Bioengineering2022 to 2025$2,381,642September 30, 2022June 30, 2027JHA, ABHINAV Kreporter.nih.gov
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate CancerNIHNational Cancer Institute2023 to 2025$2,380,224April 1, 2023March 31, 2028CHAKRABORTY, GOUTAMreporter.nih.gov
Molecular imaging of novel PARP inhibitor nanomedicine deliveryNIHNational Cancer Institute2022 to 2025$2,377,967August 12, 2022July 31, 2027VANBROCKLIN, HENRY F.reporter.nih.gov
MELT: Modulation of PSMA Expression for Lutetium TherapyNIHNational Cancer Institute2021 to 2025$2,363,818July 1, 2019June 30, 2026HOPE, THOMAS Areporter.nih.gov
Bioengineered Prostate-on Chip: Mechanisms of Stromal Dysregulation in Prostate CancerNIHNational Cancer Institute2021 to 2025$2,349,240April 7, 2021March 31, 2027MIRANTI, CYNTHIA Kreporter.nih.gov
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancerNIHNational Cancer Institute2022 to 2025$2,339,824April 1, 2022March 31, 2027GAO, ALLEN C.reporter.nih.gov
PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer ResearchNIHNational Cancer Institute2021 to 2023$2,327,659September 20, 2013July 31, 2025TANGEN, CATHERINE M.reporter.nih.gov
Real time fine needle assessment of architectural heterogeneity in prostate cancerNIHNational Cancer Institute2021 to 2025$2,327,219January 18, 2019December 31, 2025XU, GUANreporter.nih.gov
Molecular mechanisms of prostate cancer metastasisNIHNational Cancer Institute2021 to 2025$2,326,612January 1, 2015June 30, 2027ABATE-SHEN, CORYreporter.nih.gov
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate CancerNIHNational Cancer Institute2021 to 2024$2,321,414September 1, 2020May 31, 2026THAKUR, MATHEW LAXMANreporter.nih.gov
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceNIHNational Cancer Institute2021 to 2025$2,315,488April 1, 2015August 31, 2025SAWYERS, CHARLES L.reporter.nih.gov
Interplay between tumor and microenvironment in bone metastasisNIHNational Cancer Institute2021 to 2025$2,312,393April 1, 2021March 31, 2026FISHER, PAUL Breporter.nih.gov
Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopyNIHNational Cancer Institute2021 to 2025$2,308,361February 5, 2021January 31, 2027FUJIMOTO, JAMES Greporter.nih.gov
Using Prostate Health Index and MRI in Combination for Cost-effectively Detecting High-Grade Prostate CancerNIHNational Cancer Institute2021 to 2025$2,307,356September 14, 2020June 30, 2026MURPHY, ADAM Breporter.nih.gov
Super Resolution for Improved Multislice Prostate MRINIHNational Institute of Biomedical Imaging and Bioengineering2022 to 2025$2,303,815July 10, 2022May 31, 2026RIEDERER, STEPHEN Jreporter.nih.gov
Rad-pathomic deep learning models to assist radiologists in differentiating aggressive from indolent prostate cancer on MRINIHNational Cancer Institute2022 to 2025$2,302,630January 12, 2022December 31, 2026RUSU, MIRABELAreporter.nih.gov
Prostate Cancer Diagnosis by Multiparametric UltrasoundNIHNational Cancer Institute2021 to 2024$2,294,658July 1, 2020June 30, 2025FORSBERG, FLEMMINGreporter.nih.gov
HFH-MSU CSRN ACCrual Enrollment and Screening SiteNIHNational Cancer Institute2024 to 2025$2,289,116March 7, 2025December 31, 2027NESLUND-DUDAS, CHRISTINE MARIEreporter.nih.gov
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeuticsNIHNational Cancer Institute2022 to 2024$2,279,178September 15, 2020August 31, 2025BEEBE, DAVID Jreporter.nih.gov
Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic OutcomesNIHNational Cancer Institute2023 to 2025$2,274,110July 1, 2023June 30, 2028FREEDLAND, STEPHEN JAYreporter.nih.gov
Aligning financial incentives to promote rational use of active surveillance for prostate cancerNIHNational Cancer Institute2022 to 2025$2,252,166April 1, 2022March 31, 2027SHAHINIAN, VAHAKN Breporter.nih.gov
Digital Multiplexed Analysis of Circulating Nucleic Acids in Small-Volume Blood SpecimensNIHNational Institute of Biomedical Imaging and Bioengineering2022 to 2025$2,239,028August 15, 2022May 31, 2026SMITH, ANDREW MICHAELreporter.nih.gov
Rewired Signaling at the Nexus of Melanoma Metastasis and ResistanceNIHNational Cancer Institute2021 to 2022$2,234,009February 2, 2016January 31, 2023RONAI, ZEEV A.reporter.nih.gov
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate CancerNIHNational Cancer Institute2022 to 2025$2,194,673June 3, 2022May 31, 2027OYELERE, ADEGBOYEGAreporter.nih.gov
Hsp60 Regulation of Prostate Cancer ProgressionNIHNational Cancer Institute2021 to 2025$2,185,351September 1, 2021August 31, 2027CHANDRA, DHYANreporter.nih.gov
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeuticsNIHNational Cancer Institute2021 to 2025$2,182,643July 13, 2021June 30, 2027SADAR, MARIANNE Dreporter.nih.gov
Targeting AR and AR-Variants in Castration-Resistant Prostate CancerNIHNational Cancer Institute2021 to 2025$2,175,178February 1, 2021January 31, 2027DAMODARAN, CHENDILreporter.nih.gov
Diffusion Histology Imaging: A Clinical Tool to Non-Invasively Diagnose and Manage Prostate CancerNIHNational Cancer Institute2022 to 2025$2,170,868January 1, 2022December 31, 2026IPPOLITO, JOSEPH EDWARDreporter.nih.gov
Mechanisms of Prostate Cancer MetastasisNIHNational Cancer Institute2021 to 2025$2,155,774September 17, 2021August 31, 2026FREEMAN, MICHAEL R.reporter.nih.gov
A non-canonical role for EZH2 in rRNA methtlationNIHNational Cancer Institute2021 to 2025$2,146,235July 15, 2021June 30, 2026CAO, QIreporter.nih.gov
Leveraging deep learning for markerless motion management in radiation therapyNIHNational Cancer Institute2021 to 2025$2,135,070April 1, 2021March 31, 2026XING, LEIreporter.nih.gov
Exercise as Interception Therapy in Primary High Risk CancerNIHNational Cancer Institute2021 to 2024$2,107,239September 3, 2020June 30, 2026JONES, LEE Wreporter.nih.gov
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer ProgressionNIHNational Cancer Institute2021 to 2025$2,103,278January 1, 2021December 31, 2025BRENNEN, WILLIAM NATHANIELreporter.nih.gov
An AI-enabled Digital Pathology Platform for Multi-Cancer Diagnosis, Prognosis and Prediction of Therapeutic BenefitNIHNational Cancer Institute2022 to 2025$2,081,138September 5, 2022August 31, 2027MADABHUSHI, ANANTreporter.nih.gov
Preserving Erectile Function by Quantifying the Nerve-Sparing step of the Robotic ProstatectomyNIHNational Cancer Institute2023 to 2025$2,077,876July 7, 2022June 30, 2027HUNG, ANDREWreporter.nih.gov
Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancerNIHNational Cancer Institute2023 to 2025$2,067,626September 20, 2023August 31, 2028HAIMAN, CHRISTOPHER ALANreporter.nih.gov
Optimizing Treatment of Prostate Cancer in Men living with HIVNIHNational Cancer Institute2023 to 2025$2,059,152August 1, 2023June 30, 2028SIGEL, KEITH MAGNUSreporter.nih.gov
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:NIHNational Cancer Institute2022 to 2024$2,054,025September 15, 2022July 31, 2027JONES, LEE Wreporter.nih.gov
MRI Virtual Pathology of the Prostate: Multi-center multi-vendor application and validationNIHNational Cancer Institute2022 to 2023$2,049,960April 1, 2020June 30, 2026OTO, AYTEKINreporter.nih.gov
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)NIHNational Cancer Institute2023 to 2025$2,048,902July 7, 2023June 30, 2027SCHULER, AARON Dreporter.nih.gov
Estrogen pathways in the development of prostatic fibrosis and lower urinary tract dysfunctionNIHNational Institute of Diabetes and Digestive and Kidney Diseases2021 to 2024$2,046,099April 1, 2021March 31, 2026RICKE, WILLIAM Areporter.nih.gov
3D Spatial Biology of Prostate Cancer Biopsies For Earlier Identification of High Risk PatientsNIHNational Cancer Institute2024 to 2025$2,045,816September 5, 2020June 30, 2027REDER, NICHOLASreporter.nih.gov
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancerNIHNational Cancer Institute2023 to 2025$2,041,405September 21, 2023August 31, 2028KIM, HYUNG Lreporter.nih.gov
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression: A double-blind randomized controlled trialNIHNational Cancer Institute2023 to 2025$2,036,734September 1, 2023August 31, 2028COLETTA, ADRIANAreporter.nih.gov
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation TherapyNIHNational Cancer Institute2021 to 2025$2,021,205April 9, 2021March 31, 2027GIUS, DAVIDreporter.nih.gov
Single-Cell Analysis of the Noncoding Genome in Human Diseases and EvolutionNIHNational Institute of General Medical Sciences2021 to 2025$2,018,750August 13, 2021June 30, 2027LI, JINGJINGreporter.nih.gov
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patientsNIHNational Cancer Institute2021 to 2023$2,012,150March 4, 2019February 28, 2025JONAS, OLIVERreporter.nih.gov
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancerNIHNational Cancer Institute2021 to 2025$2,010,462July 1, 2021June 30, 2026JIA, LIreporter.nih.gov
Systems analysis of aggressive prostate cancer pathologyNIHNational Cancer Institute2021 to 2023$2,003,318September 1, 2019August 31, 2025COSTELLO, JAMES CHRISTOPHERreporter.nih.gov
Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted RadiotherapyNIHNational Cancer Institute2021 to 2022$2,000,000September 20, 2021August 31, 2024BOMBA, HUNTER NICOLEreporter.nih.gov
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancerNIHNational Cancer Institute2022 to 2023$2,000,000September 14, 2022August 31, 2025GAO, SONGQIreporter.nih.gov
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate CancerNIHNational Cancer Institute2022 to 2023$2,000,000August 1, 2022July 31, 2026WANG, YICHENGreporter.nih.gov
Programming Metabolically Fit TILs for ImmunotherapyNIHNational Cancer Institute2023 to 2024$2,000,000February 15, 2020August 31, 2025MEHROTRA, SHIKHARreporter.nih.gov
Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancerNIHNational Cancer Institute2024 to 2025$1,996,496September 6, 2024August 31, 2026KAHL, STEPHEN Breporter.nih.gov
Comprehensive Assessment of Cancer Theranostics ResponseNIHNational Cancer Institute2023 to 2024$1,985,840September 22, 2023August 31, 2025PERK, TIMOTHYreporter.nih.gov
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptorNIHNational Institute of General Medical Sciences2021 to 2025$1,979,921September 15, 2021June 30, 2026ROBUSTELLI, PAULreporter.nih.gov
Determining the clinical impact of gene expression testing in localized prostate cancerNIHNational Cancer Institute2021 to 2024$1,978,776September 1, 2019August 31, 2025MORGAN, TODD M.reporter.nih.gov
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic nichesNIHNational Cancer Institute2023 to 2025$1,972,155July 1, 2023June 30, 2028LANG, JOSHUAreporter.nih.gov
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,971,553September 19, 2023August 31, 2028THOMPSON, TIMOTHY CHARLESreporter.nih.gov
(PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational researchNIHNational Cancer Institute2021 to 2023$1,970,965September 1, 2019August 31, 2025CHEN, SHIUANreporter.nih.gov
Prostate Cancer Vulnerabilities to BH3 Mimetic DrugsNIHNational Cancer Institute2021 to 2025$1,965,536June 1, 2021May 31, 2026BALK, STEVEN P.reporter.nih.gov
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapyNIHNational Cancer Institute2023 to 2025$1,959,827May 1, 2023April 30, 2028FLAVELL, ROBERT RICHARDreporter.nih.gov
A novel strategy to overcome drug resistance in cancerNIHNational Cancer Institute2021 to 2025$1,956,732March 1, 2021February 28, 2027EDINGER, AIMEE Lreporter.nih.gov
Germline Determinants of Prostate Cancer EvolutionNIHNational Cancer Institute2023 to 2025$1,954,844April 1, 2023March 31, 2028SPELLMAN, PAUL T.reporter.nih.gov
Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imagingNIHNational Cancer Institute2023 to 2025$1,950,868September 13, 2023August 31, 2028LEAPMAN, MICHAEL STUARTreporter.nih.gov
Interleukin-1beta and AR-negative tumor cells in metastatic castrate-resistant prostate cancerNIHNational Cancer Institute2022 to 2025$1,945,498September 1, 2022August 31, 2027FATATIS, ALESSANDROreporter.nih.gov
Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibodyNIHNational Cancer Institute2021 to 2024$1,936,422June 1, 2020May 31, 2026MATHEW, PAULreporter.nih.gov
An integrative multi-omics approach to characterize prostate cancer risk in diverse populationsNIHNational Cancer Institute2021 to 2024$1,935,577July 16, 2021June 30, 2027MANCUSO, NICHOLASreporter.nih.gov
Targeting the colchicine binding site in tubulin for cancer therapyNIHNational Cancer Institute2021 to 2025$1,935,287January 1, 2011December 31, 2026LI, WEIreporter.nih.gov
Small-molecule therapy for metastatic castration-resistant prostate cancerNIHNational Cancer Institute2021 to 2022$1,935,175August 1, 2017August 31, 2025WU, DAQINGreporter.nih.gov
Hyperpolarized C-13 MRI for Early Detection of Aggressive Prostate Cancer in Active Surveillance PatientsNIHNational Cancer Institute2021 to 2023$1,932,408April 11, 2019March 31, 2025VIGNERON, DANIEL Breporter.nih.gov
Targeting the microtubule cytoskeleton to promote cavernous nerve regeneration and erectile function after injuryNIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,928,183September 1, 2023June 30, 2028DAVIES, KELVIN Preporter.nih.gov
Androgen Signaling in CaP with loss of MAP3K7 and CHD1NIHNational Cancer Institute2021 to 2025$1,924,438July 1, 2021June 30, 2026CRAMER, SCOTT Dreporter.nih.gov
Improving Quality of Life of Prostate Cancer Survivors with Androgen DeficiencyNIHNational Institute on Aging2021 to 2023$1,923,916August 1, 2018September 30, 2025BHASIN, SHALENDERreporter.nih.gov
Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancerNIHNational Cancer Institute2023 to 2025$1,922,720April 12, 2023March 31, 2028KIBEL, ADAM Sreporter.nih.gov
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"NIHNational Cancer Institute2023 to 2025$1,921,654June 1, 2023May 31, 2028RICKMAN, DAVID S.reporter.nih.gov
Mechanisms governing metastatic dormancy and reactivationNIHNational Cancer Institute2021 to 2022$1,915,493August 1, 2016July 31, 2023GIANCOTTI, FILIPPO Greporter.nih.gov
Drug Development of Skp2 PROTACs in CancerNIHNational Cancer Institute2023 to 2025$1,912,388May 31, 2023April 30, 2028LI, HONG-YUreporter.nih.gov
Microendoscopic Electrical Impedance Sensing for Real-time Intraoperative Surgical Margin AssessmentNIHNational Cancer Institute2021 to 2024$1,910,965July 15, 2020June 30, 2025HALTER, RYAN JOSEPHreporter.nih.gov
AR Gene Rearrangements and AR Signaling in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,909,771April 1, 2013March 31, 2028DEHM, SCOTT M.reporter.nih.gov
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignanciesNIHNational Cancer Institute2021 to 2024$1,908,434January 1, 2020December 31, 2024LOWE, SCOTT W.reporter.nih.gov
Ligand-mediated, vehicle-free delivery of small RNAsNIHNational Cancer Institute2021 to 2025$1,908,192April 1, 2018August 31, 2028KASINSKI, ANDREA Lreporter.nih.gov
Deciphering Mechanisms of Tumor-Stromal Interactions in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,908,093May 1, 2021April 30, 2027WU, BOYANGreporter.nih.gov
Targeting Mitochondrial Redox Capacity to Overcome Cancer Subtype that Regrowth After RadiationNIHNational Cancer Institute2021 to 2025$1,906,181April 1, 2021March 31, 2027CHAISWING, LUKSANAreporter.nih.gov
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancerNIHNational Cancer Institute2021 to 2025$1,900,860April 1, 2021March 31, 2027DASGUPTA, SUBHAMOYreporter.nih.gov
"Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis"NIHNational Cancer Institute2023 to 2025$1,899,979April 1, 2023March 31, 2028NOWAK, DAWID GRZEGORZreporter.nih.gov
Discriminatory Mechanisms in Early-Onset and Lethal Prostate CancerNIHNational Cancer Institute2021 to 2025$1,894,111August 13, 2021July 31, 2026COHN, BARBARA Areporter.nih.gov
Enhancement of tumor radiation response by ultrasound-driven nanobubble stimulationNIHNational Cancer Institute2021 to 2024$1,889,708August 11, 2021July 31, 2026EXNER, AGATA Areporter.nih.gov
Functional Analysis of Structure Specific Nucleases in Genome Stability and CancersNIHNational Cancer Institute2021 to 2025$1,887,170September 20, 2016August 31, 2026ZHENG, LIreporter.nih.gov
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancerNIHNational Cancer Institute2023 to 2025$1,884,679September 15, 2023August 31, 2028SUNG, KYUNG HYUNreporter.nih.gov
Breaking down tumor immune privilege through targeted hypoxia reductionNIHNational Cancer Institute2021 to 2024$1,883,414July 1, 2020June 30, 2025CURRAN, MICHAEL A.reporter.nih.gov
Inside-Out Nonlinear Gradients to Improve Diffusion MRINIHNational Cancer Institute2021 to 2025$1,881,297July 6, 2021September 30, 2026GALIANA, GIGIreporter.nih.gov
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)NIHNational Cancer Institute2023 to 2025$1,877,904September 21, 2023August 31, 2028APARICIO, ANAreporter.nih.gov
Statistical methods for genomic analysis of heterogeneous tumorsNIHNational Cancer Institute2022 to 2025$1,872,847July 8, 2022June 30, 2027WANG, WENYIreporter.nih.gov
Therapeutic targeting Wnt5A signaling for advanced prostate cancerNIHNational Cancer Institute2021 to 2025$1,872,645December 1, 2020November 30, 2026GAO, ALLEN C.reporter.nih.gov
Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancerNIHNational Cancer Institute2021 to 2024$1,871,496February 1, 2023January 31, 2026BIRMANN, BRENDA Mreporter.nih.gov
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,867,088July 1, 2023June 30, 2028LIU, XIAOQIreporter.nih.gov
Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.NIHNational Cancer Institute2021 to 2024$1,866,870March 9, 2020August 31, 2025ABATE-DAGA, DANIELreporter.nih.gov
Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based CohortNIHNational Cancer Institute2021 to 2024$1,858,613July 16, 2020June 30, 2025CAMP, NICOLA J.reporter.nih.gov
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patientsNIHNational Cancer Institute2023 to 2025$1,856,603February 1, 2023August 31, 2028HOLLENBECK, BRENT K.reporter.nih.gov
Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapyNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2024$1,852,300July 1, 2021March 31, 2026HATFIELD, STEPHEN MATTHEWreporter.nih.gov
RSI-AI: Predicting clinically significant prostate cancer to guide biopsy decisions by combining advanced tissue microstructure imaging with deep learningNIHNational Cancer Institute2021 to 2024$1,847,999August 15, 2021July 31, 2025WHITE, NATHAN SCOTTreporter.nih.gov
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVNIHNational Cancer Institute2021 to 2024$1,847,366September 8, 2020March 31, 2025MCCORMICK, DAVIDreporter.nih.gov
Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis RegulatorsNIHNational Cancer Institute2023 to 2025$1,846,447February 7, 2023January 31, 2028KELLEY, SHANA Oreporter.nih.gov
High throughput infrastructure for reaction screening and bioassaysNIHNational Center for Advancing Translational Sciences2022 to 2023$1,838,646June 1, 2022May 31, 2024COOKS, ROBERT GRAHAMreporter.nih.gov
Addressing Circulation of Guideline-Discordant Information to Promote Optimal Prostate Cancer CareNIHNational Cancer Institute2023 to 2025$1,837,936February 7, 2023January 31, 2028LOEB, STACYreporter.nih.gov
Prostate cancer risk stratification via computational 3D pathologyNIHNational Cancer Institute2022 to 2024$1,831,816July 1, 2022June 30, 2027LIU, JONATHAN T.C.reporter.nih.gov
Elevated homocysteine in African American Prostate Cancer: Association with Diet and Dietary practices, evaluating its biomarker potential, and characterizing its tumor promoting functionNIHNational Cancer Institute2022 to 2025$1,824,802April 1, 2022March 31, 2027SREEKUMAR, ARUNreporter.nih.gov
Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approachesNIHNational Cancer Institute2023 to 2025$1,823,701July 7, 2023June 30, 2028IPPOLITO, JOSEPH EDWARDreporter.nih.gov
Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancerNIHNational Cancer Institute2021 to 2025$1,819,525June 4, 2021November 30, 2026SONG, MIN SUPreporter.nih.gov
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancerNIHNational Cancer Institute2021 to 2024$1,810,625May 22, 2019April 30, 2026GOODRICH, DAVID W.reporter.nih.gov
Targeting alternative splicing for TCR discovery in small cell carcinomasNIHNational Cancer Institute2021 to 2022$1,809,996September 21, 2018August 31, 2024WITTE, OWEN N.reporter.nih.gov
Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer SurvivorsNIHNational Cancer Institute2021 to 2024$1,806,535July 23, 2020June 30, 2026GONZALEZ, BRIAN Dreporter.nih.gov
Development of Methods for a Simplified and Reliable Prostate Cancer MRI ExamNIHNational Cancer Institute2021 to 2025$1,799,393June 1, 2020November 30, 2026MAIER, STEPHAN Ereporter.nih.gov
Adaptive Percutaneous Prostate Interventions using Sensorized NeedleNIHNational Cancer Institute2021 to 2025$1,799,242August 1, 2019February 29, 2028TOKUDA, JUNICHIreporter.nih.gov
Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancerNIHNational Cancer Institute2021 to 2025$1,796,578January 1, 2019April 30, 2027JOHNSON, JEREMY JAMESreporter.nih.gov
Phase II Clinical trial of GTC in Men on Active SurveillanceNIHNational Cancer Institute2021 to 2024$1,792,639June 1, 2019May 31, 2026KUMAR, NAGI B.reporter.nih.gov
Stromal Foxf2 suppresses prostate cancer progressionNIHNational Cancer Institute2022 to 2025$1,790,773July 1, 2022May 31, 2027XIN, LIreporter.nih.gov
10-year Comparative Effectiveness and Harms of Treatments for Prostate CancerNIHNational Cancer Institute2021 to 2023$1,788,766April 1, 2019December 31, 2024BAROCAS, DANIEL Areporter.nih.gov
Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate CancerNIHNational Cancer Institute2021 to 2023$1,788,361January 1, 2019December 31, 2024SINGH, SHIVENDRAreporter.nih.gov
Tailored prostate cancer screening: addressing USPSTF priority research gaps in a racially-diverse study populationNIHNational Cancer Institute2023 to 2025$1,787,388August 1, 2023July 31, 2028LANGSTON, MARVIN EPOLIANreporter.nih.gov
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic StrategiesNIHNational Cancer Institute2021 to 2023$1,784,465December 14, 2018November 30, 2023MAHAJAN, NUPAM Preporter.nih.gov
Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancerNIHNational Cancer Institute2021 to 2025$1,783,175September 1, 2021August 31, 2026LIU, CHENGFEIreporter.nih.gov
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer OutcomesNIHNational Cancer Institute2021 to 2023$1,778,839May 1, 2019April 30, 2025JANI, ASHESHreporter.nih.gov
Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate CancerNIHNational Cancer Institute2021 to 2025$1,770,550July 1, 2021June 30, 2026LIU, CHENGFEIreporter.nih.gov
A novel AR degrader in castrate-resistant prostate cancerNIHNational Cancer Institute2023 to 2025$1,765,881August 15, 2023June 30, 2028KIM, HYEONG-REH CHOIreporter.nih.gov
Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approachNIHNational Cancer Institute2021 to 2024$1,758,201June 11, 2020May 31, 2025LYNCH, CONOR Creporter.nih.gov
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomesNIHNational Cancer Institute2023 to 2025$1,755,220September 19, 2023August 31, 2028HA, GAVINreporter.nih.gov
Glycosylation and Immune Evasion in Urologic TumorsNIHNational Cancer Institute2021 to 2023$1,754,997May 1, 2019April 30, 2026PITTERI, SHARONreporter.nih.gov
Ethical Multimodal fusion Artificial Intelligence platform (EMAP) to bridge the gap between imaging modalities: Application to prostate cancer diagnosis.NIHOffice of the Director, National Institutes of Health2025$1,753,477September 15, 2025September 14, 2026RUSU, MIRABELAreporter.nih.gov
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa CellsNIHNational Cancer Institute2021 to 2025$1,753,253June 1, 2019March 31, 2030TANG, DEAN G.reporter.nih.gov
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic EfficacyNIHNational Cancer Institute2022 to 2025$1,749,738July 1, 2022June 30, 2027LI, ZHIGUOreporter.nih.gov
Clinical Translation of Near Infrared Nerve-Specific Fluorophores for Nerve-sparing ProstatectomyNIHNational Cancer Institute2022 to 2024$1,748,403July 1, 2022June 30, 2025BARTH, CONNOR WILLIAMreporter.nih.gov
Targeting allosteric scaffolding functions of Aurora kinase A in cancerNIHNational Cancer Institute2021 to 2025$1,740,140April 1, 2021March 31, 2027LEVINSON, NICHOLAS MARKreporter.nih.gov
A dyadic exercise approach to prevent declines in physical and mental health in couples during radiation treatment for cancer: a hybrid type I efficacy-implementation trialNIHNational Cancer Institute2023 to 2025$1,737,544July 1, 2023June 30, 2028WINTERS-STONE, KERRI Mreporter.nih.gov
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,734,793January 1, 2023December 31, 2027ZHAO, DIreporter.nih.gov
RET Regulation and Targeting in Neuroendocrine Prostate CancerNIHNational Cancer Institute2022 to 2025$1,732,079May 1, 2022April 30, 2027DRAKE, JUSTIN MICHAELreporter.nih.gov
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancerNIHNational Cancer Institute2022 to 2025$1,731,077September 1, 2022August 31, 2027MATHEW, GRINUreporter.nih.gov
Personalized Risk-AdaptIve Surveillance (PRAISE) - Implications of Algorithmic BiasNIHNational Cancer Institute2021 to 2024$1,727,788September 1, 2018August 31, 2026BANSAL, AASTHAAreporter.nih.gov
MAOA and AR Reciprocal Crosstalk in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,725,441January 1, 2019December 31, 2025WU, BOYANGreporter.nih.gov
Parp Function in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,722,423March 1, 2017February 29, 2028PASCHAL, BRYCEreporter.nih.gov
MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate CancerNIHNational Cancer Institute2021 to 2023$1,720,463September 16, 2019August 31, 2025POLLACK, ALANreporter.nih.gov
De-implementation of low value castration for men with prostate cancerNIHNational Cancer Institute2021 to 2023$1,718,667January 16, 2018December 31, 2024SAINI, SAMEER DEVreporter.nih.gov
Improved Detection of Prostate Cancer with Nanoparticle-based Ultrasound Contrast Agents Targeted to PSMANIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2025$1,708,848December 15, 2017January 31, 2028EXNER, AGATA Areporter.nih.gov
The Impact of Aging on Prostate Cancer with Age-Related Disruption of Th17/Treg AxisNIHNational Cancer Institute2021 to 2025$1,707,208January 1, 2021December 31, 2026ZHANG, QIUYANGreporter.nih.gov
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE)NIHNational Cancer Institute2023 to 2025$1,705,585June 22, 2023May 31, 2028WINTERS-STONE, KERRI Mreporter.nih.gov
Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitorsNIHNational Institute of Diabetes and Digestive and Kidney Diseases2021 to 2022$1,705,226July 19, 2021March 31, 2025DRAGANSKI, ANDREW Rreporter.nih.gov
The Radium-223 Combination Therapy Space; Improving Response and Clarifying ToxicitiesNIHNational Cancer Institute2021 to 2024$1,701,190March 1, 2020February 28, 2026THOREK, DANIEL LYNDON JAFFEreporter.nih.gov
Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate CancerNIHNational Cancer Institute2021 to 2024$1,691,636May 1, 2020October 31, 2025DIAZ MECO CONDE, MARIA TERESAreporter.nih.gov
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancerNIHNational Cancer Institute2021 to 2025$1,690,924February 3, 2022June 30, 2027DOMINGO-DOMENECH, JOSEP MARIAreporter.nih.gov
Centrosome instability as a mechanism to promote localized prostate cancerNIHNational Cancer Institute2021 to 2023$1,690,509August 22, 2019July 31, 2025ROGERS, GREGORY CHARLESreporter.nih.gov
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerNIHNational Cancer Institute2021 to 2022$1,689,999September 19, 2018August 31, 2023VAN ALLEN, ELIEZER Mreporter.nih.gov
A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical ProstatectomyNIHNational Institute of Diabetes and Digestive and Kidney Diseases2021 to 2022$1,686,452September 15, 2018August 31, 2024BAKER, LISA ANNreporter.nih.gov
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPCNIHNational Cancer Institute2023 to 2025$1,679,715July 12, 2023March 31, 2028CZERNIN, JOHANNESreporter.nih.gov
Investigating lineage plasticity in castration-resistant prostate cancerNIHNational Cancer Institute2021 to 2024$1,673,048July 1, 2020June 30, 2025SHEN, MICHAEL M.reporter.nih.gov
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapyNIHNational Cancer Institute2021 to 2025$1,668,272January 1, 2021December 31, 2025PLATZ, ELIZABETH A.reporter.nih.gov
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomyNIHNational Cancer Institute2023 to 2025$1,663,456August 22, 2023July 31, 2027MEEKER, ALAN KEITHreporter.nih.gov
Targeting chemoresistant prostate cancer with novel EED inhibitorsNIHNational Cancer Institute2022 to 2025$1,655,250April 1, 2022March 31, 2028WU, DAQINGreporter.nih.gov
Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)NIHNational Cancer Institute2021 to 2023$1,653,777February 1, 2019January 31, 2025NARAYANAN, RAMESHreporter.nih.gov
Targeting Ferroptosis in Lethal RB1 Deficient Prostate CancerNIHNational Cancer Institute2022 to 2025$1,651,150April 1, 2022March 31, 2027CHEN, MINGreporter.nih.gov
Therapeutic targeting steroid sulfatase for advanced prostate cancerNIHNational Cancer Institute2021 to 2024$1,641,960September 1, 2020May 31, 2026GAO, ALLEN C.reporter.nih.gov
Collaborative genomic alterations and transcriptional control in prostate cancerNIHNational Cancer Institute2021 to 2023$1,640,685February 1, 2019January 31, 2025BARBIERI, CHRISTOPHER Ereporter.nih.gov
Engineering Large Chromosomal Deletions in Mice to Advance Precision OncologyNIHNational Cancer Institute2022 to 2025$1,637,004March 1, 2022February 28, 2027CHEN, MINGreporter.nih.gov
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancersNIHNational Cancer Institute2023 to 2025$1,633,514August 10, 2023July 31, 2028ADELAIYE-OGALA, REMIreporter.nih.gov
Role of the CD44/Hyaluronan axis in mesenchymal prostate cancerNIHNational Cancer Institute2023 to 2025$1,621,817August 1, 2023July 31, 2028DIAZ MECO CONDE, MARIA TERESAreporter.nih.gov
Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markersNIHNational Cancer Institute2022 to 2025$1,612,380September 22, 2022August 31, 2027EASTHAM, JAMES Areporter.nih.gov
Improving chemotherapy of castration-resistant prostate cancer.NIHNational Cancer Institute2021 to 2025$1,603,204August 10, 2016June 30, 2026LIU, XIAOQIreporter.nih.gov
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and ProgressionNIHNational Cancer Institute2021 to 2024$1,598,629July 7, 2020June 30, 2026RAI, PRIYAMVADAreporter.nih.gov
A novel determinant of prostate cancer growthNIHNational Cancer Institute2021 to 2025$1,596,877April 1, 2021March 31, 2026HEEMERS, HANNELOREreporter.nih.gov
Uncovering diverse genotype-phenotype relationships in prostate cancerNIHNational Cancer Institute2021 to 2024$1,587,660September 23, 2021August 31, 2026LEE, JOHN KYUNGreporter.nih.gov
Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA menNIHNational Cancer Institute2023 to 2025$1,586,636May 1, 2023April 30, 2028LIU, XUEFENGreporter.nih.gov
Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage PlasticityNIHNational Cancer Institute2022 to 2025$1,582,219July 1, 2022June 30, 2027NELSON, PETER Sreporter.nih.gov
Adipocyte regulation of tumor survival in metastatic prostate cancer: new targets for therapyNIHNational Cancer Institute2021 to 2024$1,581,561June 1, 2020May 31, 2026PODGORSKI, IZABELAreporter.nih.gov
Detection of prostate Cancer Specific Signals with Hybrid Multi-Dimensional MRINIHNational Cancer Institute2021 to 2023$1,581,168April 3, 2019March 31, 2025OTO, AYTEKINreporter.nih.gov
Differential activation of the triacylglycerol pathway in lipofibroblasts induces neurogenesis associated with prostate cancer progressionNIHNational Cancer Institute2025$1,575,170September 12, 2025July 31, 2029FRANCO CORONEL, OMARreporter.nih.gov
Role of MED1 in the AR-dependent transcription in advanced prostate cancerNIHNational Cancer Institute2021 to 2024$1,571,463March 6, 2020February 28, 2026ASANGANI, IRFAN AHMEDreporter.nih.gov
Automated Assessment for Robotic Suturing Utilizing Deep Learning AlgorithmsNIHNational Cancer Institute2021 to 2023$1,571,182April 1, 2021July 10, 2023HUNG, ANDREWreporter.nih.gov
Intracellular Self-Assembly of Theranostic Nanoparticles for Enhanced Imaging and Tumor TherapyNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2024$1,563,211July 10, 2020March 31, 2026BULTE, JEFF W.reporter.nih.gov
Examining the Relationship between Residential History at Midlife and Prostate Cancer OutcomesNIHNational Institute on Minority Health and Health Disparities2023 to 2025$1,561,820August 16, 2023February 29, 2028ZEIGLER-JOHNSON, CHARNITA M.reporter.nih.gov
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating CellsNIHNational Cancer Institute2021 to 2022$1,557,154February 3, 2016January 31, 2024BALDWIN, ALBERT SIDNEYreporter.nih.gov
Sequence-specific Hybridization Capture for Discovery of Proteoform–lncRNA Interactions in Prostate CancerNIHNational Cancer Institute2021 to 2024$1,549,624March 4, 2015December 31, 2025SMITH, LLOYD Mreporter.nih.gov
Robot-Assisted Personalized Prostate BiopsyNIHNational Cancer Institute2021 to 2025$1,543,611April 1, 2021March 31, 2027STOIANOVICI, DANreporter.nih.gov
Hormone signaling and translation control in advanced prostate cancerNIHNational Cancer Institute2022 to 2025$1,542,779December 1, 2023November 30, 2025HSIEH, ANDREW CALEBreporter.nih.gov
3D genome architecture and the origins of recurrent genomic rearrangements in prostate cancerNIHNational Cancer Institute2021 to 2024$1,541,635February 1, 2020January 31, 2026MANI, RAM SHANKARreporter.nih.gov
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate CancerNIHNational Cancer Institute2022 to 2025$1,535,622August 1, 2022July 31, 2027CHEN, MINGreporter.nih.gov
Targeting MED31-driven transcription recycling in lethal prostate cancerNIHNational Cancer Institute2023 to 2025$1,523,960July 1, 2023June 30, 2028HE, YIPINGreporter.nih.gov
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistanceNIHNational Cancer Institute2023 to 2025$1,522,620January 3, 2022August 31, 2027LIN, HUI-KUANreporter.nih.gov
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain InhibitionNIHNational Cancer Institute2021 to 2024$1,517,884September 1, 2020May 31, 2025ALUMKAL, JOSHI JAMESreporter.nih.gov
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1ANIHNational Cancer Institute2023 to 2025$1,517,182August 1, 2023July 31, 2028YU, JINDANreporter.nih.gov
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune ResponseNIHNational Cancer Institute2022 to 2025$1,515,269December 1, 2021November 30, 2027KACHHAP, SUSHANT KRISHNAreporter.nih.gov
Randomized trial of community health worker-led decision coaching to promote shared decision making for prostate cancer screening among Black male patients and their providersNIHNational Institute on Minority Health and Health Disparities2021 to 2022$1,507,485August 22, 2018March 31, 2024MAKAROV, DANIL V.reporter.nih.gov
Exosome separation and digital resolution detection of blood-based nucleic acid biomarkers for noninvasive therapeutic diagnostics in cancerNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2023$1,503,255July 15, 2020March 31, 2026CUNNINGHAM, BRIAN T.reporter.nih.gov
The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer DetectionNIHNational Cancer Institute2023 to 2025$1,497,955July 12, 2023June 30, 2028PUNNEN, SANOJreporter.nih.gov
Elucidating the molecular signaling of Cadmium CarcinogenesisNIHNational Institute of Environmental Health Sciences2022 to 2024$1,496,060June 2, 2022March 31, 2028DAMODARAN, CHENDILreporter.nih.gov
Identification of Natural Compound Combinations for Prevention of Prostate CancerNIHNational Cancer Institute2021 to 2023$1,485,787February 1, 2019January 31, 2025DIGIOVANNI, JOHNreporter.nih.gov
Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate CancerNIHNational Cancer Institute2021 to 2024$1,479,365January 1, 2018January 31, 2025BARBIERI, CHRISTOPHER Ereporter.nih.gov
The contributions of sensory nerves to bone metastasis and associated bone painNIHNational Cancer Institute2021 to 2024$1,472,125March 5, 2020February 28, 2026SHIOZAWA, YUSUKEreporter.nih.gov
Targeting androgen receptor nuclear localization in prostate cancerNIHNational Cancer Institute2022 to 2025$1,471,591June 10, 2022May 31, 2027WANG, ZHOUreporter.nih.gov
Multimodal, Multi-scale Framework for Ethical AI Model DevelopmentNIHOffice of the Director, National Institutes of Health2025$1,464,652June 30, 2025June 29, 2027GICHOYA, JUDYreporter.nih.gov
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancerNIHNational Cancer Institute2021 to 2024$1,464,602December 3, 2019November 30, 2025LUO, JUNreporter.nih.gov
A Combination Therapy to Treat Cancer-Related FatigueNIHNational Cancer Institute2021 to 2023$1,457,679December 1, 2018November 30, 2024YENNU, SRIRAMreporter.nih.gov
Simulating Ancestrally Unbiased Tumor Evolution To Interrogate Drug ResistanceNIHNational Cancer Institute2023$1,453,500September 19, 2023August 31, 2026BOSE, ROHITreporter.nih.gov
miR-205 Nanoparticle system circumvents docetaxel resistance in prostate cancerNIHNational Institute of General Medical Sciences2021 to 2024$1,453,000May 18, 2021March 31, 2026YALLAPU, MURALI MOHANreporter.nih.gov
Glutaminase I isoforms as personalized biomarkers of prostate cancerNIHNational Cancer Institute2022 to 2025$1,452,662January 1, 2022December 31, 2026HUANG, JIAOTIreporter.nih.gov
Role of JMJD1A modifications in castration resistance of prostate cancerNIHNational Cancer Institute2021 to 2024$1,440,957September 1, 2020May 31, 2026QI, JIANFEIreporter.nih.gov
Automated Assessment for Robotic Suturing Utilizing Deep Learning AlgorithmsNIHNational Cancer Institute2023 to 2025$1,438,983April 1, 2021March 31, 2026HUNG, ANDREWreporter.nih.gov
Targeting aberrant circadian regulator in advanced prostate cancerNIHNational Cancer Institute2022 to 2025$1,436,443December 15, 2021November 30, 2026CHEN, HONGWUreporter.nih.gov
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesisNIHNational Cancer Institute2022 to 2025$1,433,646March 1, 2022February 28, 2028WANG, LIEWEIreporter.nih.gov
COP1 REGULATION OF AR SIGNALING AND PROSTATE CANCER GROWTH AND THERAPY RESISTANCENIHNational Cancer Institute2023 to 2025$1,431,666May 1, 2023April 30, 2028YANG, FENGreporter.nih.gov
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,428,877July 1, 2023June 30, 2028MAHAJAN, NUPAM Preporter.nih.gov
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancerNIHNational Cancer Institute2022 to 2025$1,422,658December 9, 2021November 30, 2026ZI, XIAOLINreporter.nih.gov
Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancerNIHNational Cancer Institute2024 to 2025$1,421,960August 1, 2024July 31, 2029ZHOU, PENGBOreporter.nih.gov
Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapyNIHNational Cancer Institute2024 to 2025$1,419,727September 4, 2024August 31, 2029PONOMAREV, VLADIMIRreporter.nih.gov
Uncovering diverse genotype-phenotype relationships in prostate cancerNIHNational Cancer Institute2021$1,419,627September 23, 2021March 31, 2022LEE, JOHN KYUNGreporter.nih.gov
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostateNIHNational Cancer Institute2024 to 2025$1,419,480July 2, 2024June 30, 2028BODEI, LISAreporter.nih.gov
Men Moving Forward: A Lifestyle Intervention for African American Prostate Cancer SurvivorsNIHNational Cancer Institute2021 to 2022$1,418,002July 1, 2018June 30, 2025STOLLEY, MELINDA Rreporter.nih.gov
Epigenetic aging as a driver of racial disparities in early onset prostate cancerNIHNational Cancer Institute2024 to 2025$1,416,138September 20, 2024August 31, 2029WOLOSZYNSKA-READ, ANNAreporter.nih.gov
Etiologic Heterogeneity Between Molecular Subtypes of Prostate CancerNIHNational Cancer Institute2023 to 2024$1,410,400August 1, 2023July 31, 2028STOPSACK, KONRAD HERMANNreporter.nih.gov
Aggressive prostate cancer of African Americans is correlated with regulation of Immunoregulatory Genes in stromaNIHNational Cancer Institute2021 to 2023$1,399,904April 3, 2019March 31, 2025RAHMATPANAH, FARAH BAKHSHIANreporter.nih.gov
Comprehensive Analyses of HOXB13-regulated Transcriptional programs critical for Prostate Cancer ProgressionNIHNational Cancer Institute2023 to 2025$1,398,942March 1, 2023February 28, 2026YU, JINDANreporter.nih.gov
ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancerNIHNational Cancer Institute2024 to 2025$1,397,432April 1, 2024March 31, 2029MCCLURE, TIMOTHYreporter.nih.gov
Dissecting and targeting a novel vulnerability in aggressive Rb1 and p53 doubly deficient prostate cancerNIHNational Cancer Institute2022 to 2025$1,396,513August 1, 2022July 31, 2027LI, WENLIANGreporter.nih.gov
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy ResistanceNIHNational Cancer Institute2021 to 2024$1,392,253May 1, 2021August 31, 2024MU, PINGreporter.nih.gov
Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin EffectorNIHNational Cancer Institute2021 to 2024$1,391,249April 1, 2020March 31, 2026LU, XINreporter.nih.gov
Macrocycle inhibition of beta-catenin mediated transcription in prostate cancerNIHNational Cancer Institute2024 to 2025$1,388,993June 1, 2024May 31, 2026LOGAN, SUSAN K.reporter.nih.gov
Augmenting PSMA expression to enhance PSMA directed therapeutic efficacyNIHNational Cancer Institute2024 to 2025$1,388,233February 1, 2024January 31, 2029HAFFNER, MICHAEL Creporter.nih.gov
Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer paNIHNational Cancer Institute2021 to 2024$1,387,631September 8, 2020August 31, 2025ARCILA, MARIA Ereporter.nih.gov
Long-Term Mental Health Outcomes in Prostate Cancer Survivors and Their PartnersNIHNational Cancer Institute2023 to 2025$1,387,108June 21, 2022March 31, 2027CRUMP, CASEYreporter.nih.gov
Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRFNIHNational Cancer Institute2021 to 2024$1,383,201June 19, 2014December 31, 2024HEEMERS, HANNELOREreporter.nih.gov
Targeting early events in prostate cancer lineage plasticityNIHNational Cancer Institute2023 to 2025$1,380,656December 1, 2022November 30, 2027DEHM, SCOTT M.reporter.nih.gov
Racial Difference in Prostate CancerNIHNational Cancer Institute2021 to 2025$1,380,415April 1, 2018December 31, 2029FREEMAN, MICHAEL R.reporter.nih.gov
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate CancerNIHNational Cancer Institute2023 to 2025$1,379,959April 1, 2023March 31, 2028MAHAJAN, NUPAM Preporter.nih.gov
Multimodal dendrimer theranostics targeting aggressive subtypes of prostate cancerNIHNational Cancer Institute2024 to 2025$1,367,760September 19, 2024August 31, 2029POMPER, MARTIN Greporter.nih.gov
Molecular Mechanisms of Large Oncosome-Induced Prostate Cancer Progression and MetastasisNIHNational Cancer Institute2021 to 2023$1,363,513August 1, 2019July 31, 2025DI VIZIO, DOLORESreporter.nih.gov
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistanceNIHNational Cancer Institute2021 to 2024$1,362,712April 1, 2020March 31, 2026EDINGER, AIMEE Lreporter.nih.gov
Orally active CBP/p300 degradersNIHNational Cancer Institute2024 to 2025$1,361,184March 1, 2024February 28, 2029WANG, SHAOMENGreporter.nih.gov
KanSurvive: Testing a model for improving cancer survivorship care in rural practiceNIHNational Cancer Institute2021 to 2023$1,358,381August 23, 2019July 31, 2025KLEMP, JENNIFER ROSEreporter.nih.gov
Treatment-Induced Phenotypic Reprogramming in Prostate CancerNIHNational Cancer Institute2021 to 2023$1,356,338February 1, 2019February 28, 2025KYPRIANOU, NATASHAreporter.nih.gov
Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapyNIHNational Cancer Institute2024 to 2025$1,353,393July 1, 2024June 30, 2029QING, KUNreporter.nih.gov
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancerNIHNational Cancer Institute2023 to 2025$1,348,066July 3, 2023June 30, 2028ZARIF, JELANI CHINELOreporter.nih.gov
Delineate the Role of GSTP1 in Advanced Prostate CancerNIHNational Cancer Institute2023 to 2025$1,346,711July 14, 2023May 31, 2028STOYANOVA, TANYA Ireporter.nih.gov
Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistanceNIHNational Cancer Institute2024 to 2025$1,344,370May 1, 2024April 30, 2029HUANG, JIAOTIreporter.nih.gov
Biology and vulnerabilities of POU2F3+ tuft cell-like carcinomasNIHNational Cancer Institute2024 to 2025$1,341,635May 1, 2024April 30, 2029VAKOC, CHRISTOPHERreporter.nih.gov
Localized SDF-1 mRNA nanoparticle delivery for treating erectile dysfunction.NIHNational Institute of Diabetes and Digestive and Kidney Diseases2023 to 2025$1,338,910May 1, 2022April 30, 2027SUK, JUNG SOOreporter.nih.gov
Regulation of prostate epithelial basal cell plasticityNIHNational Cancer Institute2022 to 2025$1,329,440September 25, 2015February 28, 2027WANG, ZHUreporter.nih.gov
Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer CharacterizationNIHNational Cancer Institute2021 to 2023$1,326,744February 21, 2018January 31, 2025CATANA, CIPRIANreporter.nih.gov
Cognitive impairment associated with androgen deprivation therapy for prostate cancerNIHNational Cancer Institute2021 to 2023$1,325,841December 1, 2018November 30, 2024MORILAK, DAVID Areporter.nih.gov
A novel role for EZH2 in A-to-I RNA editing in prostate cancerNIHNational Cancer Institute2024 to 2025$1,325,538February 5, 2024January 31, 2029CAO, QIreporter.nih.gov
Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer AggressivenessNIHNational Cancer Institute2022 to 2025$1,323,242June 17, 2022May 31, 2027POLLACK, ALANreporter.nih.gov
Cell Survival Advantage in Cadmium Induced CarcinogenesisNIHNational Institute of Environmental Health Sciences2021 to 2025$1,322,105July 15, 2021April 30, 2026DAMODARAN, CHENDILreporter.nih.gov
Small Molecule ERG Inhibitors for Prostate CancerNIHNational Cancer Institute2024 to 2025$1,317,983July 1, 2024June 30, 2029BUSHWELLER, JOHN HACKETTreporter.nih.gov
Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate CancerNIHNational Cancer Institute2024 to 2025$1,306,861September 1, 2024August 31, 2029YU, JINDANreporter.nih.gov
Development of Next Generation Galeterone Analogs for Prostate Cancer TherapyNIHNational Cancer Institute2021 to 2022$1,305,208March 1, 2018February 29, 2024NJAR, VINCENT COLLINS OFUKAreporter.nih.gov
The role of focal adhesion kinase in therapy resistant prostate tumorsNIHNational Cancer Institute2023 to 2025$1,304,790July 7, 2023May 31, 2028HUANG, JIAOTIreporter.nih.gov
Cause and Effect Relationships Between Glycation and the Ancestry Specific Tumor StromaNIHNational Cancer Institute2023 to 2025$1,301,277January 1, 2023December 31, 2027TURNER, DAVID PAULreporter.nih.gov
SArcopenia in Men with Prostate Cancer undergoing ADT (SAP-ADT)NIHNational Cancer Institute2024 to 2025$1,300,486January 12, 2024December 31, 2028GARCIA, JOSE M.reporter.nih.gov
Defining the Mechanistic Basis of Bacterial Androgen Production in Dampening Anti-Tumor Immunity and Promoting Resistance to Androgen Receptor Axis-Targeted Therapies for Metastatic Prostate CancerNIHNational Cancer Institute2024 to 2025$1,299,526July 1, 2024June 30, 2029SFANOS, KAREN SANDELLreporter.nih.gov
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate CancerNIHNational Cancer Institute2024 to 2025$1,296,178August 15, 2024July 31, 2029MAHAJAN, NUPAM Preporter.nih.gov
Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociNIHNational Cancer Institute2022 to 2023$1,291,109September 1, 2022July 31, 2024GAYTHER, SIMON ANDREWreporter.nih.gov
Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalizationNIHNational Cancer Institute2024 to 2025$1,289,060September 17, 2024August 31, 2029DEWARAJA, YUNI Kreporter.nih.gov
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPCNIHNational Cancer Institute2021 to 2023$1,283,103March 1, 2019August 31, 2024TANG, DEAN G.reporter.nih.gov
Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic developmentNIHNational Cancer Institute2021 to 2022$1,281,844April 1, 2018March 31, 2024WITTE, OWEN N.reporter.nih.gov
The role of tumor-macrophage hybrid cells in prostate cancer metastasisNIHNational Cancer Institute2024 to 2025$1,274,336May 1, 2024April 30, 2029HUANG, TIM H.-M.reporter.nih.gov
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate CancerNIHNational Cancer Institute2021 to 2022$1,271,825August 1, 2018July 31, 2023PASQUALINI, RENATAreporter.nih.gov
Preventing Falls and Frailty in Prostate Cancer Survivors: GET FIT ProstateNIHNational Cancer Institute2021 to 2022$1,270,849July 23, 2018June 30, 2024WINTERS-STONE, KERRI Mreporter.nih.gov
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate CancerNIHNational Cancer Institute2021 to 2025$1,267,741September 14, 2021August 31, 2028SPRATT, DANIEL EIDELBERGreporter.nih.gov
Defining Molecular Determinants of Lineage Plasticity as a Mechanism of Treatment Resistance in Prostate CancerNIHNational Cancer Institute2021 to 2023$1,267,148August 1, 2019July 31, 2024RICKMAN, DAVID S.reporter.nih.gov
Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood TestNIHNational Cancer Institute2024 to 2025$1,265,472September 1, 2024August 31, 2029DI VIZIO, DOLORESreporter.nih.gov
Computational Feature Profiling and Modeling for Prostate Cancer Detection and Risk StratificationNIHNational Cancer Institute2024 to 2025$1,261,345December 5, 2023November 30, 2028ARNOLD, COREY WELLSreporter.nih.gov
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatmentNIHNational Cancer Institute2023 to 2025$1,249,397April 3, 2023March 31, 2028BROWN, ERIC Jreporter.nih.gov
Elucidating a novel molecular biomarker for castration-resistant prostate cancerNIHNational Cancer Institute2023 to 2025$1,245,269September 26, 2012July 31, 2028SHARIFI, NIMAreporter.nih.gov
Analysis of epithelial heterogeneity in prostate development and cancerNIHNational Cancer Institute2021 to 2023$1,242,555April 1, 2019August 31, 2024SHEN, MICHAEL M.reporter.nih.gov
Metabolic Rewiring Promotes AA PCa by Regulating Stromal-Epithelial InteractionNIHNational Cancer Institute2021 to 2023$1,237,018July 1, 2019June 30, 2025SREEKUMAR, ARUNreporter.nih.gov
Harnessing low-field MRI and robotics to enable personalized incisionless prostate surgeryNIHNational Cancer Institute2024 to 2025$1,233,428June 1, 2024May 31, 2029GRISSOM, WILLIAM Areporter.nih.gov
Posttranslational modifications of glucocorticoid receptor associated with drug-resistance in prostate cancerNIHNational Cancer Institute2024 to 2025$1,230,702April 9, 2024March 31, 2029ADELAIYE-OGALA, REMIreporter.nih.gov
The Role of YY1 in Castration-Resistant Prostate CancerNIHNational Cancer Institute2023 to 2025$1,229,263July 15, 2021August 31, 2026CAI, LINGreporter.nih.gov
Developing therapies to improve enzalutamide in CRPCNIHNational Cancer Institute2023 to 2025$1,228,701December 1, 2022November 30, 2027QIAN, ZHENG DAVIDreporter.nih.gov
Image-guided ultrasound ablation for precision targeting of prostate cancerNIHNational Cancer Institute2021 to 2022$1,225,974August 7, 2018July 31, 2024BURDETTE, EVERETTE Creporter.nih.gov
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate CancerNIHNational Cancer Institute2021 to 2024$1,224,612January 1, 2020December 31, 2025LEBEAU, AARON MATTHEWreporter.nih.gov
Multi-cohort validation of machine learning radiogenomic models (ML-RGx) to predict late toxicity in prostate cancerNIHNational Cancer Institute2024 to 2025$1,223,116July 1, 2024June 30, 2026KERNS, SARAH L.reporter.nih.gov
Defining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate CancerNIHNational Cancer Institute2021 to 2024$1,219,521August 15, 2020April 30, 2025NELSON, PETER Sreporter.nih.gov
AKR1C3 Inhibitors as Chemotherapeutic PotentiatorsNIHNational Cancer Institute2021 to 2023$1,214,980January 1, 2019December 31, 2024TRIPPIER, PAULreporter.nih.gov
Therapy-induced cognitive impairment in a rat model of prostate cancerNIHNational Cancer Institute2023 to 2025$1,214,059August 1, 2023July 31, 2028MORILAK, DAVID Areporter.nih.gov
MMS22L loss and PARP inhibition in prostate cancerNIHNational Cancer Institute2023 to 2025$1,207,916April 1, 2023March 31, 2028JIA, LIreporter.nih.gov
Novel ctDNA biomarker for androgen therapy in metastatic prostate cancerNIHNational Cancer Institute2024 to 2025$1,206,494December 6, 2023November 30, 2028MAHER, CHRISTOPHER Areporter.nih.gov
Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate CancerNIHNational Cancer Institute2024 to 2025$1,205,236July 5, 2024June 30, 2026GRYDER, BERKLEY Ereporter.nih.gov
Molecular Recognition of Proteins and Ligand DesignNIHNational Institute of General Medical Sciences2021 to 2023$1,200,327July 1, 1990March 31, 2025JORGENSEN, WILLIAM L.reporter.nih.gov
Peptoid conjugates targeting prostate cancerNIHNational Cancer Institute2024 to 2025$1,199,699August 1, 2024July 31, 2029GARABEDIAN, MICHAEL J.reporter.nih.gov
Development of fast diffusion magnetic resonance fingerprinting of the prostate to avoid unnecessary biopsiesNIHNational Cancer Institute2024 to 2025$1,199,506July 1, 2024June 30, 2026KAYAT BITTENCOURT, LEONARDOreporter.nih.gov
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancerNIHNational Cancer Institute2024 to 2025$1,188,864March 1, 2024February 28, 2029BRENNEN, WILLIAM NATHANIELreporter.nih.gov
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancerNIHNational Cancer Institute2021 to 2023$1,188,004August 1, 2019July 31, 2025ARMSTRONG, ANDREW Jreporter.nih.gov
Urology practice consolidation and care for men with prostate cancerNIHNational Cancer Institute2024 to 2025$1,178,696February 1, 2024January 31, 2029SHAHINIAN, VAHAKN Breporter.nih.gov
Targeting eIF4A1-dependent HK2 translation axis for prevention of castration-resistant prostate cancerNIHNational Cancer Institute2021 to 2023$1,168,124December 1, 2018November 30, 2024DENG, YIBINreporter.nih.gov
WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate CancerNIHNational Cancer Institute2023 to 2025$1,166,752June 1, 2023May 31, 2028BALK, STEVEN P.reporter.nih.gov
Fluorescence image guided surgery, adjuvant PDT, and the immune responseNIHNational Institute of Biomedical Imaging and Bioengineering2024 to 2025$1,164,624July 1, 2024April 30, 2028BASILION, JAMES PETERreporter.nih.gov
Cell free nucleic acid-based biomarkers in advanced prostate cancerNIHNational Cancer Institute2021 to 2022$1,162,841August 1, 2017January 31, 2025WANG, LIANGreporter.nih.gov
Targeting pancreatic cancer metastases with TargefrinNIHNational Cancer Institute2025$1,162,000April 30, 2024August 31, 2027BAGGIO, CARLOreporter.nih.gov
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancerNIHNational Cancer Institute2024 to 2025$1,161,698March 1, 2022March 31, 2027NEVALAINEN, MARJA Treporter.nih.gov
Clinical Translation of dual-modality transrectal ultrasound and photoacoustic imaging for detection of aggressive human prostate cancerNIHNational Cancer Institute2023 to 2024$1,160,336September 19, 2023August 31, 2028KOTHAPALLI, SRI RAJASEKHARreporter.nih.gov
Protein kinase C signaling in prostate cancer health disparitiesNIHNational Cancer Institute2024 to 2025$1,159,789June 8, 2023May 31, 2028KAZANIETZ, MARCELO G.reporter.nih.gov
VIPCare: Virtual Predictive Care workflow with EHR integrated surveillance for optimalfollow-up care management for Cancer PatientsNIHNational Cancer Institute2025$1,154,996September 1, 2023August 31, 2027BAGCHI, SUGATOreporter.nih.gov
Development of small molecule therapeutics targeting AR-V7 for prostate cancerNIHNational Cancer Institute2025$1,150,471May 2, 2024April 30, 2027AU, CHEUK MAN CHERIEreporter.nih.gov
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumorsNIHNational Cancer Institute2025$1,150,000August 18, 2025July 31, 2027SCHULTZ, KENNETHreporter.nih.gov
A Real-Time Hyperspectral Laparoscopic Stereo Imaging System for Robot-Assisted SurgeryNIHNational Cancer Institute2024 to 2025$1,149,405March 1, 2024August 31, 2029FEI, BAOWEIreporter.nih.gov
A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancerNIHNational Cancer Institute2024 to 2025$1,149,396July 12, 2024June 30, 2026CAO, QIreporter.nih.gov
Mitochondrial and nuclear functions of NKX3.1 in regulating oxidative stress in prostate cancerNIHNational Cancer Institute2021 to 2023$1,145,770December 1, 2018November 30, 2024ABATE-SHEN, CORYreporter.nih.gov
Overcoming Drug Resistance of Castration-Resistant Prostate CancerNIHNational Cancer Institute2022 to 2025$1,143,461September 1, 2011June 30, 2027LIU, XIAOQIreporter.nih.gov
Image-guided TRAIL-enhanced CAR T-cell immunotherapyNIHNational Cancer Institute2021 to 2022$1,142,717April 1, 2018March 31, 2023PONOMAREV, VLADIMIRreporter.nih.gov
The role of histidine phosphorylation in the DNA alkylation damage responseNIHNational Cancer Institute2023 to 2025$1,136,219February 1, 2023January 31, 2028PEI, HUADONGreporter.nih.gov
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancerNIHNational Cancer Institute2022 to 2023$1,136,140March 1, 2022August 31, 2023NEVALAINEN, MARJA Treporter.nih.gov
Defining Tumor Microenvironmental Mediators of Prostate Cancer Metastasis and Therapy ResistanceNIHNational Cancer Institute2024 to 2025$1,132,633July 1, 2024June 30, 2029HURLEY, PAULA JILLreporter.nih.gov
Novel Therapeutic Approaches for Aggressive Prostate CancerNIHNational Cancer Institute2023 to 2025$1,130,311June 1, 2023May 31, 2028MERCURIO, ARTHUR Mreporter.nih.gov
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patientsNIHNational Cancer Institute2024 to 2025$1,128,792July 1, 2024June 30, 2029BHOWMICK, NEIL A.reporter.nih.gov
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancerNIHNational Cancer Institute2023 to 2025$1,127,164April 1, 2023March 31, 2028LEE, JIHOONreporter.nih.gov
The origins of metabolic reprogramming in prostate cancerNIHNational Cancer Institute2021 to 2023$1,124,770August 2, 2019July 31, 2024GOLDSTEIN, ANDREW Sreporter.nih.gov
Hybrid Intelligence for Trustable Diagnosis And Patient Management of Prostate Cancer (HIT-PIRADS)NIHNational Cancer Institute2023 to 2025$1,124,300June 22, 2023May 31, 2027BAGCI, ULASreporter.nih.gov
Targeted delivery of multimodal therapy for reducing prostate cancer disparityNIHNational Cancer Institute2022 to 2024$1,122,741December 9, 2021November 30, 2026LIU, RUNHUA RUNAreporter.nih.gov
Tumor immune and glycan biomarkers for progressive prostate cancerNIHNational Cancer Institute2021 to 2022$1,114,661December 4, 2017July 31, 2025WU, JENNIFER Dreporter.nih.gov
Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtypeNIHNational Cancer Institute2024 to 2025$1,114,585April 1, 2024March 31, 2029LIU, BINreporter.nih.gov
Functional characterization of prostate cancer risk loci by high throughput sequencingNIHNational Cancer Institute2021 to 2023$1,112,470July 1, 2020June 30, 2025WANG, LIANGreporter.nih.gov
Testing ATAD2 as a new therapeutic target for advanced prostate cancerNIHNational Cancer Institute2024 to 2025$1,110,884July 1, 2024June 30, 2029STOYANOVA, TANYA Ireporter.nih.gov
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer AggressivenessNIHNational Cancer Institute2022 to 2024$1,108,399January 29, 2022November 30, 2025RODRIGUEZ-BRAVO, VERONICAreporter.nih.gov
Multiparametric Photoacoustic Imaging-Based Identification of Aggressive Prostate CancerNIHOffice of the Director, National Institutes of Health2021 to 2023$1,107,777September 17, 2019August 31, 2025ZHANG, HAICHONGreporter.nih.gov
An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.NIHNational Cancer Institute2025$1,106,781September 1, 2023July 31, 2027WILLIAMS, WILLIAM VALENTINEreporter.nih.gov
Mechanisms by which histone methyltransferases regulate nuclear receptor activity and response to therapy in hormone-driven tumors.NIHNational Cancer Institute2023 to 2025$1,105,006March 16, 2023February 29, 2028TOSKA, ENEDAreporter.nih.gov
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerNIHNational Cancer Institute2021 to 2022$1,103,223June 1, 2018May 31, 2024HE, JIANGreporter.nih.gov
Development of a novel MYC inhibitor for cancer therapyNIHNational Cancer Institute2025$1,102,729September 12, 2025August 31, 2027VOLLRATH, BENreporter.nih.gov
Targeting angiotensin and inflammation to prevent radiotherapy-induced bladder toxicity.NIHNational Cancer Institute2024 to 2025$1,100,715August 1, 2024July 31, 2029MARPLES, BRIANreporter.nih.gov
Leveraging common genetic variation to reduce misclassification of non-diseased individuals and unnecessary health care utilization attributable to surrogate biomarkersNIHNational Institute of General Medical Sciences2021 to 2023$1,097,409September 17, 2019June 30, 2025MOSLEY, JONATHAN DAVIDreporter.nih.gov
Opening the Therapeutic Window for PSMA-Targeted Molecular RadiotherapyNIHNational Cancer Institute2021 to 2024$1,094,534May 1, 2019April 30, 2025THOREK, DANIEL LYNDON JAFFEreporter.nih.gov
Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progressionNIHNational Cancer Institute2023 to 2025$1,093,197January 18, 2023December 31, 2027WANG, GUOCANreporter.nih.gov
Multi-Modality Quantitative Imaging for Evaluation of Response to Cancer TherapyNIHNational Cancer Institute2021 to 2022$1,092,846September 19, 2011June 30, 2024DU, YONGreporter.nih.gov
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancerNIHNational Cancer Institute2021 to 2022$1,091,437May 1, 2020April 30, 2023SWEENEY, CHRISTOPHER Jreporter.nih.gov
Ghana IntegRative Approach to Cancer ResEarch Training: The Grace ProgramNIHNational Cancer Institute2021 to 2025$1,087,889May 19, 2021April 30, 2027YAMOAH, KOSJreporter.nih.gov
Molecular Mechanisms Underlying Luminal- Neuroendocrine TransdifferentiationNIHNational Cancer Institute2024 to 2025$1,082,472September 1, 2024August 31, 2029ZHAO, CHANGSHENGreporter.nih.gov
Neurocognitive Changes from Long-Term Androgen Deprivation Therapy in Prostate Cancer PatientsNIHNational Cancer Institute2021 to 2023$1,080,943August 13, 2018July 31, 2025CHAO, HERTA HUEY-ANreporter.nih.gov
Regulation of Androgen Receptor by NXTAR Long non-coding RNA in Prostate Cancer and its Therapeutic ImplicationsNIHNational Cancer Institute2024 to 2025$1,079,624August 9, 2024July 31, 2029MAHAJAN, NUPAM Preporter.nih.gov
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylationNIHNational Cancer Institute2023 to 2024$1,076,279April 1, 2023March 31, 2028VISWANATHAN, SRINIVAS RAGHAVANreporter.nih.gov
Determine the Role of Histone Methyltransferase ASH1L in Metastatic Prostate CancerNIHNational Cancer Institute2024 to 2025$1,075,398September 18, 2024August 31, 2029ZHAO, DIreporter.nih.gov
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate CancerNIHNational Cancer Institute2021 to 2022$1,067,292September 1, 2021August 31, 2023RYAN, CHARLES JAMESreporter.nih.gov
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factorsNIHNational Cancer Institute2024 to 2025$1,065,298March 1, 2024February 28, 2029DOMINGO-DOMENECH, JOSEP MARIAreporter.nih.gov
Targeting AR variants in advanced prostate cancerNIHNational Cancer Institute2021 to 2023$1,062,505January 1, 2019December 31, 2025GAO, ALLEN C.reporter.nih.gov
A novel mitotic regulatory axis in neuroendocrine prostate cancerNIHNational Cancer Institute2021 to 2023$1,061,109July 2, 2019June 30, 2025WANG, QIMING JANEreporter.nih.gov
Targeting CD133 for imaging and therapy in prostate cancerNIHNational Cancer Institute2021 to 2023$1,060,004July 1, 2021June 30, 2025LEBEAU, AARON MATTHEWreporter.nih.gov
Elucidating the Role of Trop2 in Prostate CancerNIHNational Cancer Institute2023 to 2025$1,055,277April 1, 2025March 31, 2027STOYANOVA, TANYA Ireporter.nih.gov
Targeting Genomic Instability in Lethal Neuroendocrine Prostate CancerNIHNational Cancer Institute2021 to 2022$1,049,860June 6, 2018May 31, 2023GRAEBER, THOMAS Greporter.nih.gov
Proteomic Analysis of Blood Plasma using High Throughput SequencersNIHNational Institute of General Medical Sciences2021$1,045,419September 1, 2020August 31, 2024MCPIKE, MARK PATRICKreporter.nih.gov
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapyNIHNational Cancer Institute2024 to 2025$1,043,520January 1, 2024November 30, 2028HONG, JIYONGreporter.nih.gov
Defining the Biological Arc of Grade Group 1 Prostate CancerNIHNational Cancer Institute2023 to 2025$1,039,044August 1, 2023July 31, 2028SALAMI, SIMPA SAMUELreporter.nih.gov
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implicationsNIHNational Cancer Institute2021 to 2022$1,038,564September 1, 2018August 31, 2023ASHWORTH, ALANreporter.nih.gov
Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to enhance MRI diagnostic capabilities in Prostate CancerNIHNational Cancer Institute2024 to 2025$1,035,539May 17, 2023June 30, 2028LISS, MICHAEL ANDREreporter.nih.gov
The role for alcohol-induced Golgi disorganization in the progression of prostate cancerNIHNational Institute on Alcohol Abuse and Alcoholism2021 to 2023$1,029,375August 2, 2019July 31, 2025PETROSYAN, ARMENreporter.nih.gov
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate CancerNIHNational Cancer Institute2021 to 2023$1,029,364April 1, 2020February 6, 2024DATTA, KAUSTUBHreporter.nih.gov
Influence of bone microenvironment on drug resistance in prostate cancer bone metastasisNIHNational Cancer Institute2022 to 2024$1,028,449April 19, 2019December 31, 2025LI, XIAOHONGreporter.nih.gov
Developing New Treatment Strategies for Neuroendocrine Prostate CancerNIHNational Cancer Institute2024 to 2025$1,027,307April 1, 2024March 31, 2029ALUMKAL, JOSHI JAMESreporter.nih.gov
Neuroendocrine differentiation post anti-androgenic therapy: Role of Tribbles 2NIHNational Cancer Institute2023 to 2025$1,025,716April 20, 2023March 31, 2028GHOSH, JAGADANANDAreporter.nih.gov
Robot-Enabled Natural Orifice ProstatectomyNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2022$1,024,937April 1, 2019December 31, 2024WEBSTER, ROBERT JAMESreporter.nih.gov
SUPPORT SERVICES FOR THE PLCO ETIOLOGIC&EARLY MARKER STUDIES (PLCO EEMS)NIHNational Cancer Institute2021$1,024,263July 20, 2020July 19, 2021RILEY, THOMASreporter.nih.gov
Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate CancerNIHNational Cancer Institute2025$1,022,522June 4, 2025May 31, 2027RAMAMURTHY, VIDYA Preporter.nih.gov
Novel Radioimmunotherapy Strategies for Prostate CancerNIHNational Cancer Institute2021 to 2023$1,020,311July 1, 2019June 30, 2025LEBEAU, AARON MATTHEWreporter.nih.gov
Nucleic Acid Nanoparticle-based Monoclonal Antibody MimicsNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2025$1,017,571September 1, 2021August 31, 2028KHISAMUTDINOV, EMILreporter.nih.gov
Refining castration use for recurrent prostate cancerNIHNational Cancer Institute2021 to 2023$1,013,797May 1, 2020April 30, 2025TSODIKOV, ALEXANDERreporter.nih.gov
Enabling Technology to Study Mechanosensitive and Mechanoresistant Cancer Cells in FlowNIHNational Cancer Institute2021 to 2023$1,012,035August 1, 2021June 30, 2024KING, MICHAEL R.reporter.nih.gov
Validation of predictive liquid biomarkers for patients with metastatic prostate cancerNIHNational Cancer Institute2023 to 2025$1,011,140June 1, 2021May 31, 2027LANG, JOSHUAreporter.nih.gov
KAPS Biotech: A novel biomarker to improve prostate cancer diagnosisNIHNational Institute on Minority Health and Health Disparities2021 to 2022$1,004,696September 18, 2018May 31, 2025UNDERWOOD, WILLIEreporter.nih.gov
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancerNIHNational Cancer Institute2024 to 2025$999,441April 1, 2024March 31, 2029LOU, ZHENKUNreporter.nih.gov
Urine Diagnostic Tool for the Detection of High-grade Prostate CancerNIHNational Cancer Institute2021$995,327September 1, 2020August 31, 2022NIKNAFS, YASHAR SHARIFIreporter.nih.gov
Acupuncture for Cognitive Health in Older Survivors of Prostate Cancer (ACHIEVE)NIHNational Cancer Institute2022 to 2025$990,335August 1, 2022July 31, 2027LIOU, KEVIN Treporter.nih.gov
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate CancerNIHNational Cancer Institute2023 to 2024$989,509September 1, 2021August 31, 2026HALABI, SUSANreporter.nih.gov
Development of synthetic sphingolipids for prostate cancer therapyNIHNational Cancer Institute2021$989,405September 24, 2020December 31, 2023MCCRACKEN, ALISON NICOLEreporter.nih.gov
Genomic bases for African geo-ethnic prostate cancer health disparityNIHNational Cancer Institute2024 to 2025$987,297April 1, 2024March 31, 2029HAYES, VANESSA MARIEreporter.nih.gov
Prostate Cancer Health Disparity: Role of PDEFNIHNational Cancer Institute2022 to 2024$978,524July 1, 2020June 30, 2026KOUL, HARI Kreporter.nih.gov
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica NanoparticlesNIHNational Cancer Institute2021 to 2023$973,528March 1, 2020June 29, 2023BRADBURY, MICHELLE Sreporter.nih.gov
Investigating the impact of chromosomal instability on prostate cancer aggressivenessNIHNational Cancer Institute2024 to 2025$970,708July 8, 2024June 30, 2026RODRIGUEZ-BRAVO, VERONICAreporter.nih.gov
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone MetastasesNIHNational Cancer Institute2021 to 2022$967,985September 5, 2018August 31, 2024ROWLEY, DAVID Rreporter.nih.gov
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapyNIHNational Cancer Institute2023 to 2025$967,953February 1, 2022January 31, 2027SHARIFI, NIMAreporter.nih.gov
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate TumorigenesisNIHNational Cancer Institute2021 to 2022$967,882January 8, 2018December 31, 2023ZHOU, PENGBOreporter.nih.gov
Elucidating the Role of Tryptophan Hydroxylase 1 in Neuroendocrine Prostate CancerNIHNational Cancer Institute2024 to 2025$967,136July 1, 2024June 30, 2026WU, BOYANGreporter.nih.gov
Comprehensive analyses of HOXB13-regulated transcriptional programs critical for prostate cancer progressionNIHNational Cancer Institute2021 to 2022$963,452March 4, 2021February 28, 2023YU, JINDANreporter.nih.gov
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)NIHNational Cancer Institute2021 to 2022$953,221June 1, 2019May 31, 2024LIU, XUEFENGreporter.nih.gov
RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer MetastasisNIHNational Cancer Institute2023 to 2025$949,275August 18, 2022May 31, 2028YANG, WEIreporter.nih.gov
Endothelial-to-osteoblast transition in prostate cancer bone metastasisNIHNational Cancer Institute2021 to 2023$942,760April 1, 2013July 31, 2025LIN, SUE-HWAreporter.nih.gov
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and AgingNIHNational Institute on Aging2021 to 2025$938,505August 15, 2021April 30, 2027BASARIA, SHEHZADreporter.nih.gov
Enhanced imaging and treatment of aggressive subtypes of prostate cancerNIHNational Cancer Institute2021 to 2023$927,472April 1, 2009November 30, 2023POMPER, MARTIN Greporter.nih.gov
Statistical Methods for Cancer Detection Using BiomarkersNIHNational Cancer Institute2021 to 2023$923,763March 11, 2019February 28, 2025HUANG, YIJIANreporter.nih.gov
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancerNIHNational Cancer Institute2024 to 2025$904,360April 5, 2024March 31, 2029DOMINGO-DOMENECH, JOSEP MARIAreporter.nih.gov
Clinical Qualification of Imaging and Fluid-Based Tumor Monitoring Biomarkers for Metastatic Castration Resistant Prostate CancerNIHNational Cancer Institute2021 to 2022$887,683July 1, 2020June 30, 2023SCHWARTZ, LAWRENCE Hreporter.nih.gov
Targeting Drug-Resistant Castration Resistant Prostate Cancer via LIMK2NIHNational Cancer Institute2021 to 2024$885,644March 1, 2020February 28, 2026RATLIFF, TIMOTHY L.reporter.nih.gov
Heparan Sulfate in Prostate CancerNIHNational Cancer Institute2021 to 2023$884,619April 8, 2023March 31, 2024WANG, LIANCHUNreporter.nih.gov
Elucidating the Role of UCHL1 in Aggressive Prostate CancerNIHNational Cancer Institute2022 to 2024$881,744June 15, 2020May 31, 2025STOYANOVA, TANYA Ireporter.nih.gov
Clinical and pre-clinical investigation of extracellular vesicles as a mechanism of toxicity in the bladder of prostate cancer patients treated with radiotherapyNIHNational Cancer Institute2024 to 2025$880,945April 5, 2024March 31, 2029LEE, YI-FENreporter.nih.gov
Role and targeting of PRMT5 in prostate cancerNIHNational Cancer Institute2021$880,195June 9, 2017May 31, 2023HU, CHANG-DENGreporter.nih.gov
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy ResistanceNIHNational Cancer Institute2024 to 2025$877,496May 1, 2021August 31, 2026MU, PINGreporter.nih.gov
The Role of YY1 in Castration-Resistant Prostate CancerNIHNational Cancer Institute2021 to 2022$872,419July 15, 2021May 31, 2023CAI, LINGreporter.nih.gov
Statistical modeling to support population and translational cancer researchNIHNational Cancer Institute2021 to 2025$870,818September 20, 2017August 31, 2028GULATI, ROMANreporter.nih.gov
Enhanced imaging and treatment of aggressive subtypes of prostate cancerNIHNational Cancer Institute2024 to 2025$857,013April 15, 2024May 31, 2027POMPER, MARTIN Greporter.nih.gov
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeuticsNIHNational Cancer Institute2021$854,255September 15, 2020August 31, 2022BEEBE, DAVID Jreporter.nih.gov
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate CancerNIHNational Cancer Institute2021 to 2022$853,319September 17, 2018August 31, 2023ARONSON, WILLIAM Jreporter.nih.gov
CDK8/19 inhibitors for therapy of advanced prostate cancerNIHNational Cancer Institute2021$846,340September 23, 2015May 31, 2023CHEN, MENGQIANreporter.nih.gov
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate CancerNIHNational Cancer Institute2025$839,781September 15, 2022July 31, 2027JONES, LEE Wreporter.nih.gov
Biochemical, structural and molecular dissection of androgen receptor transcriptional activityNIHNational Institute of General Medical Sciences2022 to 2024$834,935September 1, 2022August 31, 2025WASMUTH, ELIZABETH VICTORINAreporter.nih.gov
Defining PARP Inhibitor Response and Resistance in Prostate CancerNIHNational Cancer Institute2021 to 2025$832,680July 1, 2021June 30, 2026LOMBARD, ALANreporter.nih.gov
Integrating Genomics and Metabolomics to Develop Predictive Models of Prostate Cancer in Multiethnic MenNIHNational Cancer Institute2022 to 2024$830,017February 1, 2020June 30, 2025DARST, BURCU FRANCESreporter.nih.gov
Uncovering the heterogenous role of senescence in prostate immune suppression and tumorigenesisNIHNational Cancer Institute2024 to 2025$820,121April 1, 2024March 31, 2029RUSCETTI, MARCUS A.reporter.nih.gov
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)NIHNational Cancer Institute2021 to 2022$819,276January 1, 2018December 31, 2023LIU, ZHI-PINGreporter.nih.gov
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor DegradationNIHNational Cancer Institute2024 to 2025$816,333July 15, 2024August 31, 2029MU, PINGreporter.nih.gov
Adaptive resistance to AR inhibitors in hypoxia by GPT1NIHNational Cancer Institute2023 to 2025$810,138April 18, 2023March 31, 2029QIAN, ZHENG DAVIDreporter.nih.gov
Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADSNIHNational Cancer Institute2021$803,082May 1, 2018August 31, 2023ONOFREY, JOHN AARONreporter.nih.gov
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancerNIHNational Cancer Institute2021 to 2023$802,660December 1, 2019June 9, 2023SHARIFI, NIMAreporter.nih.gov
Understanding Resistance to Next Generation AntiandrogensNIHNational Cancer Institute2021 to 2022$800,118May 1, 2012December 31, 2023SAWYERS, CHARLES L.reporter.nih.gov
Systems analysis of the prostate cancer epigenomeNIHNational Cancer Institute2021 to 2024$793,216August 14, 2020April 11, 2025CHEN, ZHONGreporter.nih.gov
Leveraging implementation science to accelerate adoption of shorter-course radiation for breast and prostate cancerNIHNational Cancer Institute2022 to 2025$789,098December 1, 2022November 30, 2025GILLESPIE, ERIN FAYEreporter.nih.gov
Arsenic and other co-metals in the San Carlos Apache drinking waterNIHNational Cancer Institute2021 to 2025$785,110September 1, 2021August 31, 2026SAMUEL-NAKAMURA, CHRISTINEreporter.nih.gov
Competition, Bundled Care Payment, and Low-Value Cancer CareNIHNational Cancer Institute2021 to 2023$783,984December 1, 2018November 30, 2024O'NEIL, BROCKreporter.nih.gov
Preserving Erectile Function by Quantifying the Nerve-Sparing step of the Robotic ProstatectomyNIHNational Cancer Institute2022 to 2023$780,062July 7, 2022July 10, 2023HUNG, ANDREWreporter.nih.gov
Active surveillance and patient reported outcomes in a diverse population of prostate cancer patientsNIHNational Cancer Institute2021 to 2022$777,468August 1, 2017July 31, 2023GOMEZ, SCARLETT Lreporter.nih.gov
Integrin-mediated mechanisms of prostate cancer progressionNIHNational Cancer Institute2021 to 2022$777,452July 15, 2018June 30, 2025LANGUINO, LUCIA R.reporter.nih.gov

Organizations

OrganizationPlaceNIH awardsNIH amountNSF awardsNSF amount
Dana-Farber Cancer InstBoston, MA16$97.6 million0$0
Johns Hopkins UniversityBaltimore, MD35$51 million0$0
Mayo Clinic RochesterRochester, MN14$42.4 million0$0
Fred Hutchinson Cancer CenterSeattle, WA22$38.8 million0$0
University of California, San FranciscoSan Francisco, CA32$34.4 million0$0
Sloan-Kettering Inst Can ResearchNew York, NY30$33.7 million0$0
University of TX MD Anderson Can CTRHouston, TX24$29.8 million0$0
University of Michigan at Ann ArborAnn Arbor, MI24$29.5 million0$0
Duke UniversityDurham, NC26$28.9 million0$0
Washington UniversitySaint Louis, MO18$26.4 million0$0
Weill Medical Coll of Cornell UnivNew York, NY22$25.3 million0$0
Brigham and Women's HospitalBoston, MA15$24.9 million0$0
University of California Los AngelesLos Angeles, CA23$24.6 million0$0
Stanford UniversityStanford, CA16$21.4 million0$0
Cedars-Sinai Medical CenterLos Angeles, CA20$21.1 million0$0
Emory UniversityAtlanta, GA14$20.2 million0$0
University of Southern CaliforniaLos Angeles, CA14$18.8 million0$0
University of Wisconsin-MadisonMadison, WI18$18.3 million0$0
Columbia University Health SciencesNew York, NY13$16.6 million0$0
Case Western Reserve UniversityCleveland, OH13$16.3 million0$0
University of MinnesotaMinneapolis, MN12$15.9 million0$0
Oregon Health & Science UniversityPortland, OR10$15 million0$0
H. Lee Moffitt Cancer CTR & Res InstTampa, FL10$14.1 million0$0
University of KentuckyLexington, KY9$13.7 million0$0
Thomas Jefferson UniversityPhiladelphia, PA10$13.3 million0$0
University of California at DavisDavis, CA10$13.2 million0$0
Icahn School of Medicine at Mount SinaiNew York, NY9$12.6 million0$0
University of Texas HLTH Science CenterSan Antonio, TX12$12.5 million0$0
Northwestern University at ChicagoChicago, IL14$12.2 million0$0
University of UtahSalt Lake City, UT8$11.7 million0$0
Roswell Park Cancer Institute CorpBuffalo, NY10$11.5 million0$0
Louisiana State UniversityBaton Rouge, LA1$11.3 million0$0
Beckman Research Institute/city of HopeDuarte, CA10$11 million0$0
University of WashingtonSeattle, WA9$10.7 million0$0
University of Miami School of MedicineCoral Gables, FL10$10.7 million0$0
Yale UniversityNew Haven, CT11$9.8 million0$0
University of Nebraska Medical CenterOmaha, NE7$8.7 million0$0
Baylor College of MedicineHouston, TX7$8.5 million0$0
Purdue UniversityWest Lafayette, IN5$8.3 million0$0
University of California-IrvineIrvine, CA7$8 million0$0
New York University School of MedicineNew York, NY8$7.8 million0$0
Ut Southwestern Medical CenterDallas, TX14$7.5 million0$0
Medical College of WisconsinMilwaukee, WI5$7.1 million0$0
Cleveland Clinic Lerner Com-CwruCleveland, OH9$6.6 million0$0
Massachusetts General HospitalBoston, MA5$6.5 million0$0
Washington State UniversityPullman, WA7$6.1 million0$0
University of ChicagoChicago, IL7$5.8 million0$0
Beth Israel Deaconess Medical CenterBoston, MA3$5.7 million0$0
Texas A&m University Health Science CTRCollege Station, TX4$5.7 million0$0
SUNY at Stony BrookStony Brook, NY7$5.7 million0$0
University of Pittsburgh at PittsburghPittsburgh, PA5$5.3 million0$0
Vanderbilt University Medical CenterNashville, TN5$5.3 million0$0
Fred Hutchinson Cancer Research CenterSeattle, WA13$5.2 million0$0
University of PennsylvaniaPhiladelphia, PA9$5.2 million0$0
University of VirginiaCharlottesville, VA5$5 million0$0
University of RochesterRochester, NY4$4.9 million0$0
University of Maryland BaltimoreBaltimore, MD5$4.9 million0$0
Cancer Targeted Technology, LLCWoodinville, WA3$4.8 million0$0
University of ArizonaTucson, AZ6$4.5 million0$0
University of Colorado DenverAurora, CO3$4.4 million0$0
University of Illinois at Urbana-ChampaignUrbana, IL3$4.4 million0$0
Virginia Commonwealth UniversityRichmond, VA4$4.3 million0$0
Cold Spring Harbor LaboratoryCold Spring Harbor, NY2$4 million0$0
Dartmouth CollegeHanover, NH2$3.9 million0$0
Albert Einstein College of MedicineBronx, NY4$3.7 million0$0
Wayne State UniversityDetroit, MI4$3.6 million0$0
University of Tennessee Health Sci CTRMemphis, TN2$3.6 million0$0
University of HawaiiHonolulu, HI2$3.5 million0$0
University of Texas HLTH Sci CTR HoustonHouston, TX3$3.4 million0$0
Univ of North Carolina Chapel HillChapel Hill, NC5$3.3 million0$0
Indiana University IndianapolisIndianapolis, IN3$3.3 million0$0
Ge Medical Systems Information Technologies, INCNiskayuna, NY1$3.1 million0$0
Pennsylvania State Univ Hershey Med CTRHershey, PA1$2.9 million0$0
SUNY at BuffaloAmherst, NY2$2.9 million0$0
Louisiana State Univ HSC ShreveportShreveport, LA3$2.8 million0$0
Boston University Medical CampusBoston, MA1$2.7 million0$0
Tulane University of LouisianaNew Orleans, LA3$2.7 million0$0
University of Illinois at ChicagoChicago, IL3$2.7 million0$0
RBHS -Cancer Institute of New JerseyNew Brunswick, NJ3$2.6 million0$0
North Carolina Central UniversityDurham, NC1$2.6 million0$0
University of California, San DiegoLa Jolla, CA5$2.6 million0$0
Ohio State UniversityColumbus, OH2$2.5 million0$0
Provincial Health Services AuthorityVancouver2$2.5 million0$0
Massachusetts Institute of TechnologyCambridge, MA1$2.3 million0$0
Henry Ford Health + Michigan State University Health SciencesEast Lansing, MI1$2.3 million0$0
Wake Forest University Health SciencesWinston-Salem, NC3$2.3 million0$0
Sanford Burnham Prebys Medical Discovery InstituteLa Jolla, CA1$2.2 million0$0
Georgia Tech Research CorporationAtlanta, GA1$2.2 million0$0
Public Health InstituteOakland, CA2$2.1 million0$0
Qmis, LLCCrete, IL1$2 million0$0
Syntrix Biosystems, Inc.Auburn, WA1$2 million0$0
Alpenglow Biosciences, Inc.Seattle, WA1$2 million0$0
Vanderbilt UniversityNashville, TN2$2 million0$0
Molecular Theranostics, LLCBeachwood, OH1$2 million0$0
Immunova Therapeutics, LLCMonrovia, CA1$2 million0$0
Lipo-Immuno Tech, LLCMount Pleasant, SC1$2 million0$0
Manzanita Pharmaceuticals, Inc.Woodside, CA1$2 million0$0
University of California-Santa CruzSanta Cruz, CA2$2 million0$0
Aiq Solutions, Inc.Madison, WI1$2 million0$0
Univ of Massachusetts Med SCH WorcesterWorcester, MA3$2 million0$0

Funding by fiscal year

Fiscal yearNIH awardsNIH amountNSF awardsNSF amount
2025427$250,699,3830$0
2024490$236,403,3600$0
2023494$237,749,5700$0
2022469$229,796,6950$0
2021481$223,799,3630$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunityNumberAgencyListingClosesAward ceilingWhy it matches
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)PA-24-254NIHJuly 12, 2027Not listedNotice number printed on 12 awards here
NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)PA-24-194NIHMay 7, 2027Not listedNotice number printed on 3 awards here
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)PA-24-181NIHMay 8, 2027Not listedNotice number printed on 1 award here
Emerging Global Leader Award (K43 Independent Clinical Trial Required)PAR-24-295NIHDecember 3, 2026Not listedNotice number printed on 1 award here
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)PAR-27-089NIH93.395November 2, 2026Not listedSame assistance listing 93.395 as 246 awards here
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)PAR-26-152NIH93.395November 11, 2026Not listedSame assistance listing 93.395 as 246 awards here
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)PAR-27-088NIH93.395November 20, 2026Not listedSame assistance listing 93.395 as 246 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)PAR-24-214NIH93.395January 7, 2027$375,000Same assistance listing 93.395 as 246 awards here
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)PAR-25-079NIH93.395January 7, 2027$500,000Same assistance listing 93.395 as 246 awards here
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)PAR-25-081NIH93.395January 7, 2027$499,999Same assistance listing 93.395 as 246 awards here
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)RFA-CA-27-005NIH93.395January 11, 2027$700,000Same assistance listing 93.395 as 246 awards here
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)PAR-27-009NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 246 awards here
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)RFA-CA-26-010NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 246 awards here
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)RFA-CA-27-003NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 246 awards here
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)PA-27-100NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 246 awards here
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)PA-27-102NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 246 awards here
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)RFA-CA-28-003NIH93.395June 11, 2027$600,000Same assistance listing 93.395 as 246 awards here
Successor-in-Interest (Type 6 Parent Clinical Trial Optional)PA-24-253NIH93.395July 17, 2027Not listedSame assistance listing 93.395 as 246 awards here
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)PA-25-080NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 246 awards here
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)PAR-24-325NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 246 awards here

Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.